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CHAPTER I
INTRODUCTION
Epidemiology and Burden of Cardiovascular Diseases
Cardiovascular diseases (CVD) remain the most common devastating health
problem for men and women worldwide, accounting for 18.6 million deaths in 2019
globally1. Myocardial infarction (MI), a common endpoint for ischemic heart
disease/coronary artery diseases, is a leading cause of CVD deaths worldwide. Thanks to
measures to reduce risk factors as well as advances in therapies for coronary
revascularization, the incidence of MI and associated fatalities rates have been steadily
decreasing overtime2, though the American Heart Association (AHA) projects a new MI case
is diagnosed every 40 seconds in the United States (US) 1. An average of 600,000 American
will suffer new heart attacks and 200,000 will have recurrent attacks in 2021 1. While the
current standard of care is to open the occluded vessel and reduce the time to reperfusion,
patients who survive remain at a high risk for recurrent MI and heart failure (HF). Heart
failure developing after MI hospitalization is very prevalent and is approximately 20-30%
at the first year after discharge for MI3. The economic burden of CVD (direct and indirect
cost) for the US healthcare system is enormous, amounting to $300 billion per year and is
expected to increase rapidly to $1.1 trillion in 2035 1.
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Ischemia/Reperfusion Injury
One of the primary conditions of CVD is myocardial infarction (MI), caused by
ischemia/reperfusion (I/R) injury leading to irreversible cardiomyocyte loss. Myocardial
infarction is defined as insufficient blood flow to the heart, resulting in the formation of
infarct injury4. During ischemia, the anaerobic glycolysis prevails in cardiomyocytes,
leading to accumulation of hydrogen ion and decrease in cell pH. Cardiac acidosis causes
the Na+/H+ exchanger remove excess H+ ion, overloading the cell with Na+ ion, which in
turn produces calcium overload due to the reverse operation of sodium-calcium exchanger.
Ischemia also depletes ATP because of reduction in oxidative phosphorylation, deactivating
Na+/K+ ATPase which is responsible Ca2+ efflux. Likewise, the reuptake of calcium back to
the endoplasmic reticulum by the sarco/endoplasmic reticulum Ca 2+-ATPase (SERCA)
pump is decreased, leading to further accumulation of cytosolic Ca 2+. Excessive cytosolic
Ca2+ causes osmotic swelling and induces necrosis via action of Ca 2+-dependent proteases
and cellular structure disruption.
During reperfusion, oxygen is re-introduced by restoration of blood flow, resuming
oxidative phosphorylation. ATP-dependent hypercontracture in Ca2+ overloaded myocytes
and pH normalization induce the opening of a non-selective channel, the mitochondrial
permeability transition pore (mPTP). In addition, the restoration of oxidative
phosphorylation causes a burst of reactive oxygen species (ROS). ROS damage proteins,
lipids, nucleic acids, which further disrupt cellular structure. Furthermore, mPTP opening
activates inflammatory and pro-thrombogenic cascades, inducing release of cytokine and
apoptosis.
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Because the heart has limited ability to regenerate, the infarcted region becomes
scarred; the remodeling process ensues, leading to heart failure. The 5-year survival rate of
HF patients remains at 50% in spite of advances in therapeutic intervention 5. Therefore the
introduction of novel treatments to salvage damaged and vulnerable cardiomyocytes after
MI injury, thus preventing the loss of cardiac function is urgently necessary 6; 7.
In acute MI (AMI), an infarct kills 25% of the ventricle can cause a loss of as many as one
billion cardiomyocytes8. Because the heart is often considered as a post mitotic organ with
limited capacity for self-renewal, the infarcted region becomes fibrotic and scarred and
remodeling occurs. The damaged and remodeled heart has lost contractile capacity due to
the loss of cardiomyocytes and the increased stiffness of the ventricle, leading to the
development of heart failure as a result. Prognosis for HF remains poor as the 5-year
survival rate of HF failure is 50% with an increase in the risk of sudden cardiac arrest 9.
Several studies have shown a strong correlation between infarct size and mortality 10; 11.
Overall, larger infarct size is associated with worse clinical outcomes, including the
likelihood that patients will experience heart failure, stroke, and death 11. Therefore the
introduction of novel treatments to salvage damaged and vulnerable cardiomyocytes after
MI injury is urgently necessary.
Over the past decades, extensive studies on MI pathophysiological mechanisms have
resulted in the development of various experimental interventions, including
pharmacologic and nonpharmacologic protective strategies. Numerous therapeutic
treatments have been proposed to protect the ischemic myocardium with potential
cardioprotective effects in experimental animal models. However, only a few have been
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translated into positive results in clinical

practice 12.

Ischemic pre-, per-, post-, remote-

conditioning (a series of controlled brief ischemia and reperfusion cycles), and
pharmacological intervention have been shown to mitigate the I/R injury and limit
myocardial infarct size in preclinical situations 13. Unfortunately, most of the clinical trials
yield conflicting or underpowered results 14; 15. For instance, reperfusion therapy combined
with agents such as ATP-sensitive potassium channel openers, Na+/H+ exchange inhibitors,
glycogen synthase kinase-

GSK-

inhibitor adenosine receptor agonist cyclosporin A

and erythropoietin showed infarct size-limiting effects and improved cardiac function in

experimental animals16. However, most protective agents failed to reproduce meaningful
impact in human AMI patients due to notable discrepancies between preclinical
experiments and clinical setting including species differences in cardiomyocytes, age,
treatment for concomitant diseases, and practical considerations in patients 16.
In recent years, potential uses of extracellular vesicles (EV) in the cardiovascular
field as sources for therapeutic applications and diagnostic biomarkers have gained
immense interest. EV from stem cells can activate beneficial signaling pathways in CVD,
leading to improvement in cardiac function and smaller infarct size 17; 18; 19. These processes
are controlled by a variety of protein, nucleic acids, small molecules and paracrine factors
released from stem cells in the damaged myocardium. As administration of EV has been
shown to mediate cardioprotective properties, they represent a new frontier for novel
approaches toward cardioprotection.
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Extracellular Membranous Vesicles Released from Cells
EVs are a broad, heterogeneous group of membrane-enclosed structures used by all
prokaryotic and eukaryotic cells to carry bioactive molecules including proteins, lipids, and
nucleic acids. EVs serve as a means for intercellular communication, by triggering receptorbased signaling, and by delivery of their contents or cargo. Based on cellular origin and
classification of the International Society of Extracellular Vesicles (ISEV), EVs can be
subdivided into three subclasses roughly on the basis of size and their release mechanisms,
including exosomes (40-100 nm), released by multivesicular body, microvesicles (1001,000 nm), and apoptotic bodies (100-5,000 nm), released from direct budding from the
cytoplasmic membrane 20; 21. However, there is a lack of consensus on specific markers for
EV subpopulations such as exosomes, microvesicles/microparticles20. Furthermore,
common EV isolation methods (differential centrifugation or commercial kits) do not
achieve fully separation of EV from non-vesicular entities. Therefore, we will use the term
EV in the place of exosomes as encouraged by )SEV in this document 20; 22. Please note

that our preparations and characterizations are not different from those commonly used in
exosome studies

Initially, EV were viewed as by-products of cell homeostasis or cell damage, perhaps
containing cellular garbage for disposal The first report about the presence of EV in
extracellular space came from a study of intracellular compartments that mediate

transferrin endocytosis and recycling of the transferrin receptor 23. In recent decades, the
interest in EV has exploded, with an exponential increase in scientific publication over the
years24. EV are thought to play a crucial role in cell-to-cell communication and a means of
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transferring molecules between cells. For example, one of the earliest EV studies reported
that EV from dendritic cells carry functional major histocompatibility complex class I, II
that can prime T lymphocytes to induce antitumor immune response 25. Moreover, EV
facilitate the transfer of proteins, lipids, nucleic acids (mRNA, miRNA, DNA), organelles
(mitochondria) from cell to cell and are attributed to the development of several diseases,
including cancer, neurodegenerative disease, heart failure and liver disease 26. These
features have prompted researchers to explore EV as useful biomarkers in cancer and
other ailments, as they carry cell content as cargo, and that content contains information
about the cell that produced the EV. Furthermore, EV have been proposed to be potential
carriers for drug delivery due to their cell membrane composition and immune privileged
status. For example, EV-encapsulated paclitaxel produces stronger antineoplastic efficacy
than conventional treatments, including small molecular entities, proteins, miRNA and
mRNA. Importantly, exosomes do not invoke an immune response and thus are not cleared
from the circulation by the immune system, nor cause rejection27. Despite intensive
research and a growing body of literature, EV biology is in its infancy and we are just
beginning to understand the involvement of EVs in cellular physiology and
pathophysiology.
Extracellular Vesicle Biogenesis, Release and Uptake
The biogenesis and cargo composition of EV vary between different parental cell
types, and in the same cell type in different physiological/pathological states 21. Exosomes
are considered a particular fraction of the EV population defined by size and by origin from
the endosomal cellular compartment, though exosomes can also be derived from outward
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budding of the plasma membrane in T

cells 28.

Exosomal biogenesis starts by inward

budding of the early endosome to form intraluminal vesicles (ILV), leading to the formation
of multivesicular bodies (MVB). During the formation of ILV, certain cytoplasmic and
membrane proteins are integrated into them. The accumulated ILV in the MVB lumen then
have two possible destinies. One, they may deliver their payload with lysosome for
degradation of vesicular content. Two, they may fuse with cytoplasmic membrane to
release vesicles to the extracellular milieu by endocytic pathway. Cargo loading into ILV is
mediated by two general mechanisms: endosomal-sorting complex required for transport
(ESCRT)-dependent and ESCRT-independent pathways. The ESCRT complex -0, -I, -II, -III.
are recruited to endosomal membrane s cytosol for the sorting of selected proteins to ILV

which requires ubiquitination of cytosolic domains of exosomal cargoes 29. In addition to its

role in sequestration of ubiquitinated cargos, the ESCRT machinery also facilitates
generation of membrane curvature on endosomes. Combination of ESCRT-I and II is
reported to induce formation of inward budding structures by stabilizing the bud neck on
the biogenesis of MVB using giant unilamellar vesicles and purified ESCRT complexes 30.
After the budding process to form ILV is completed, vacuolar protein sorting associated
protein 4 (Vps4) provides energy for the ESCRT complex to separate from the MVB
membrane and recycle complex for additional rounds of function. On the other hand, ILV
can be generated at the endosomal membrane in the absence of ESCRT. The ESCRTindependent pathway depends on lipid raft microdomains and requires lipid ceramide and
neutral sphingomyelinase type II (nSMase2), an enzyme that converts sphingomyelin
located in the MVB membrane to ceramide. Inhibition of nSMase2 with GW4869 blocks
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production and release of

exosomes31.

Other proteins involved in cargo loading in both

ESCRT-dependent/independent sorting pathways are transmembrane proteins belonging
to the tetraspanin family, including CD63, CD9, CD81 and CD82. CD63 is particularly
abundant in MVB and exosomes and are useful markers for exosome characterization 32.
After the MVB matures, it is transported toward the cell membrane by actin and
microtubules. Membrane fusion between the MVB and the plasma membrane then results
in EV being secreted into the extracellular space21. This process relies on small GTPases
such as Rab-27a/b, -7, -11, -31, -35 and soluble N-ethylmaleimide-sensitive-factor
attachment protein receptors (SNARES) family proteins like YKTS6, VAMP7. Rab-27a/b are
in charge of the tethering of MVBs to plasma membrane33, while the other v-SNAREs
including VAMP3 and VAMP7, in concert with the ATPase N-ethylmaleimide sensitive
factor (NSF), are responsible for the docking and fusion of MVBs with cellular membrane,
releasing exosomes into the extracellular space34. In addition, one study reported that
calcium influx can enhance exosome release in hematopoietic K562 cell lines35. An increase
in formation of large MVB and release of exosomes are observed with treatment using
monensin, a sodium ionophore that increases intracellular Ca 2+ by reversing the Na+/Ca2+
exchanger. Treatment with Ca2+ chelator abrogates the intracellular calcium-induced EV
release, whereas EV secretion increases by Ca2+ ionophore. Intraluminal calcium levels are
regulated by thapsigargin-sensitive Ca2+ pump and inositol 1,4,5-inositoltriphosphate IP3
receptor35.
The binding of EV to their target cells is likely dependent on proteins expressed on
the EV surface and receptors on the plasma membrane of recipient cells. EV bind to their
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recipient cells by using integrin, tetraspanin, heparan sulfate proteoglycan, lipid and
extracellular matrix components. For instance, integrin on EV has been shown to interact
with intercellular adhesion molecules (ICAM) of target cells to promote docking and uptake
of EV. Treatment with antibodies against integrin or its ligand ICAM decreases EV uptake
by dendritic cells36. Other molecules such as tetraspanin also can contribute to the docking
of EV to the target cell membrane37. Blocking the binding site of tetraspanin CD81 or CD9
with antibodies reduces EV uptake by dendritic cells36. Once bound to recipient cells, EV
can commit to various fates. EV can attach to membrane receptors of target cell to
modulate signaling pathways25; 38. For example, follicular dendritic cells-derived
microvesicles carrying MHC class II molecules and other proteins not expressed by
recipient cells bind and stimulate B cells 39. Alternatively, in order to elicit a response at
recipient cells, EV can be engulfed by caveolin- and clathrin-mediated endocytosis,
macropinocytosis, or phagocytosis, depending on vesicle size 32. There are also findings that
highlight the role of lipid raft domains within the plasma membrane in EV internalization.
These rafts can be found in both caveolin-and clathrin-dependent endocytosis. Depletion of
cholesterol disrupts these rafts and reduces EVs uptake 40.
After binding with membrane of recipient cells and uptaken by different
mechanisms, EVs follow the endocytic pathway to reach MVB, leading to degradation of EV
contents at lysosome. In order to avoid being targeted by lysosome, EV can fuse with the
endosome limiting membrane. This process is not entirely understood, although protein
Alix, phosphatidylinositol-3-phosphate, and lipid lysobisphosphatidic acid (LBPA) appear
to control this event41. The back-fusion is thought to be important for delivery of
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intraluminal nucleic acid payloads such as miRNA. On the other hand, EV can dock and
merge directly with plasma membranes to release their material into the cytoplasm of
recipient cells by membrane fusion42; 43; 44. The process of direct fusion is associated with
GTPase Rab proteins, Lamp-1, SNAREs and Sec1/Munc-18 related proteins (SM proteins)42.
There is evidence that direct fusion of EV from metastatic melanoma cells with the
membrane of normal cell is determined by lipid composition of tumor cell membrane and
the low acidity condition of malignant tumor43. Additionally, some studies indicated the
presence of endogenous retrovirus class I proteins syncytin-1 and syncytin-2 on the
surface of placenta-derived EV promotes the fusion of EV with recipient cell membranes.
Attenuation of proper maturation of syncytin with furin inhibitors significantly reduces EV
uptake, suggesting the important role of both syncytin-1 and syncytin-2 in EV fusion
events44.
Extracellular Vesicles Composition
The complexity of EV-derived components has been constantly updated with data
from many proteomic and genomic studies. ExoCarta, a public resource database of
datasets from eukaryotic-derived EV, contains information on 41,860 protein entries, 4,946
mRNA entries, 2,838 miRNA entries and 1,116 lipid entries, thus illustrating the complex
composition of EV with various potential functions 45.

Protein Components
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Generally, EV are enriched with proteins required for their biogenesis, including
component proteins of ESCRT machinery, and of the tetraspanin family (CD63, CD81, CD82,
and CD9). Other proteins include cytoskeleton components (actin, myosin, cofilin-1,
tubulins), heat shock proteins (HSP70, HSP90), antigen presentation class I/II, metabolic
enzymes, signaling proteins (GTPase, transforming protein RhoA), and ribosomal proteins.
Certain protein components are consistently abundant in EVs (CD63, CD81, HSP70, and
TSG101). In fact, they are widely accepted as EV marker proteins and can be used to
demonstrate the purity of EV preparations 20; 46. However, there are some reports about
their presence in apoptotic bodies47. Additionally, different producer cells and cell culture
conditions influence the types of specific proteins expressed in EVs. EV-derived proteins
have been shown to produce measurable changes in behavior of receiving cells. For
example, EVs isolated from dendritic cells can transfer TLR4, a cell membrane receptor to
TLR4 deficient cells and trigger inflammatory responses to lipopolysaccharides (LPS)
stimulation in those recipient cells 48. In another study, EVs were shown to shuttle a specific
set of synaptic proteins including AMPA receptor to the presynaptic terminal49. These
findings support the role of EVs as important mediators for transferring receptors and
other protein cargo from cell to cell, inducing functional changes in recipient cells.
Lipid Components
Aside from proteins and nucleic acids components, EV are also enriched in
arachidonic acid (AA), and its prostaglandin derivatives (e.g., prostaglandin E2 (PGE2), 15deoxy- -12,14-prostaglandin J2 (15d-PGJ2)), cholesterol, phosphatidylserine, phosphatidic
acid, sphingomyelin, and other fatty acids that are involved in MBV/ILV/EV formation and
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cargo sorting into MVB. In one study, fatty acids and prostaglandin brought by EV were
accumulated in recipient RBL-2H3 cells allowing micromolar concentrations of
prostaglandin to trigger further biological responses 50. Therefore, endosomal PGE2 and/or
15d-PGJ2 may serve to provide intracellular PGE2 for signaling. The EV-derived AA
transferred by EVs also can be utilized by cyclooxygenase (COX) and PGE synthase in
endoplasmic reticulum of recipient cells, resulting in additional PGE2 synthesis. EV-derived
lipids can bind with lipid binding proteins, including fatty acid binding proteins (FABP) or
nuclear receptors such as peroxisome proliferator-activated receptors (PPARs) in cells that
uptake EV. This interaction forms AA/FABP/PPARs cytosolic complex and enables PPARs
to exert biological functions in the nucleus 51. EV isolated from activated T lymphocytes are
internalized via endogenous phosphatidylserine receptors, increase cholesterol
accumulation and proinflammatory cytokine production in monocytes and macrophages,
thus promoting atherogenesis52. These findings further support EV as efficient mediator for
cell-to-cell communication via lipid-induced signaling and gene expression.
Nucleic Acids Components
EV carry within them a heterogeneous population of RNA molecules which have also
been found to be involved in intercellular communication. Initial report showed that EV
RNA content consisted of mature miRNAs and mRNAs with size ranging from 200
nucleotides to 5kb53. Further comprehensive RNA sequencing studies have found the
presence of most known non-coding RNA species, including ribosomal RNAs (rRNAs), long
non-coding RNAs (lncRNAs), PIWI-interacting RNAs (piRNAs), transfer RNAs (tRNAs),
small nuclear RNAs (snoRNAs), YRNAs and vault RNAs (vtRNAs) 54; 55. In human plasma-
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derived EV RNA species, microRNA is the most abundant, accounting for over 42.32% of
raw counts and 76.20% of all mappable counts 54. Once RNAs such as miRNAs and intact
mRNAs are loaded into EV, they can be functional when transferred by EV between cells.
Messenger RNA
Many studies have reported mRNA as EV cargo and EV-derived mRNA function in
recipient cells. Among EV-derived RNA species, mRNA is one of the least abundant EV
RNAs, consisting of about 2.1% of all mapped RNAs in human plasma-derived EV54. The
average length of EV mRNAs is smaller than 1000nt. In recipient cells, mRNA can function
as a template for protein production. This event was reported by the presence of reporter
proteins translated from mRNA transported from glioblastoma to endothelial cells 56 or
between mast cells53. In the co-culture model of HEK293T cells and glioblastoma,
translation of transferred mRNA was started within one hour after EV uptake by recipient
cells57. The cell-to-cell transfer and active translation of EV mRNA were also reported in
studies using Cre-loxP technology58; 59. The transfer of functional Cre-recombinase mRNA in
red blood cell (RBC)-derived EV induces recombination in Purkinje neurons of floxed
reporter mice58. Furthermore, to distinguish protein cargo and newly synthesized proteins
in target cells, Maugeri et al. used lipid nanoparticles to deliver mRNA encoding human
erythropoietin (EPO) to epithelial cells which was packaged into epithelial cells EV. These
mRNAs were protected in EV and able to produce human EPO in recipient mouse cells 59.
Additionally, RBC-derived EV electroporated with mRNA for Cas9 have been used to
deliver RNAs for CRISPR-Cas9 genome editing system which mediated functional gene
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editing in recipient

cells60.

These studies support that EV are able to deliver functional

mRNA to recipient cells effectively.
Long non-coding RNA
EV also contain long non-coding RNA (lncRNA) and circular RNA (circRNA). The
lncRNA are defined as transcripts exceeding 200 nucleotides, which are not translated into
protein. While the circRNAs are circular closed loop single stranded RNAs derived from
protein encoding genes, primarily the introns, which may encode proteins but also have
aspects of non-coding RNAs. LncRNA and circ RNA are known to function to mediate cell
signaling, especially in the development of cancer. In human hepatocellular cancer cell
(HCC)-derived EV, several lncRNAs are significantly expressed in EV relative to donor cells.
Of these lncRNAs, lncRNA TUC339 is the most highly enriched. TUC339 function is
implicated in tumor cell proliferation and cell adhesion to extracellular matrix61. In another
study, lncRNA H19 in EV released from CD90+ liver cancer cells can alter the phenotype of
endothelial cells, promoting angiogenesis and cell adhesion 62. Other lncRNAs that are
enriched and released through EV include lncRNA ARSR (renal cancer)63 and lncRNA
CRNDE-h (colorectal cancer)64. The cited studies demonstrate that lncRNA can be
transferred between cells via EV and subsequently modulate cellular function of recipient
cells.
On the other hand, circRNAs act as miRNA sponges by competitive binding of
miRNAs, preventing the binding of miRNA with their target mRNAs. For instance, EVenriched circRNA-100284 isolated from arsenide-transformed cells has been shown to
promote cell proliferation and induce malignant transformation. circRNA-100284 exerts its
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inhibitory effect as a sponge of miR-217, thus increasing levels of EZH2, a transcriptional
activator, in recipient cells65. Additionally, circular RNA is highly stable and is resistant to
exonuclease-mediated degradation, and thus can be used as markers for tumor diagnosis.
For example, specific circRNAs were detected in hepatic cancer cell-derived EVs. CircRNA
expression in colorectal cancer patients was different from healthy subjects. Specifically, 67
circRNAs were absent, while 257 new circRNAs species were discovered in cancer
patients66.
MicroRNA
MicroRNAs (miRNAs) are single-stranded small non-coding RNAs (20-25
nucleotides in length) 67. miRNAs are among important post-transcriptional regulators for
protein-coding genes. Since their discovery in C. elegans in 1993 68, fully one-third of
human mRNAs have been predicted to be targets of miRNAs 69. The biogenesis of miRNAs
begins with the transcription by RNA polymerase II to generate the primary miRNA (primiRNA) from its gene. pri-miRNA is double-stranded long RNA (1000 nt) with hairpin
structures. Because miRNA is embedded in the stem region of pri-miRNA, miRNA needs to
be released by endoribonucleases. First, Dorsha, a class 2 ribonuclease III, cleaves primiRNA near the end of the stem. This new short hairpin structure is called precursor
miRNA (pre-miRNA) and transported from the nucleus to the cytoplasm by the Exportin-5
complex. After being released from Exportin-5 in the cytoplasm, the stem-loop of premiRNA is cleaved by the Dicer complex, generating a double-stranded RNA of 22 nt. This
RNA duplex is then loaded into the RNA-induced silencing complex (RISC) where it is
unwound and a single strand (guide strand) is used to help RISC bind to the conserved
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recognition site on the target mRNAs. It is known that miRNA acts through base-pairing of
their seed sequence, nucleotides 2-7, with sequences in the -untranslated region

-UTR)

of the target mRNA70; 71. If the binding of RISC to the target mRNA is a nearly perfect match,
it will lead to mRNA degradation, whereas a partial match will lead to a translational
inhibition67; 70. In addition, miRNAs and their cognate binding sites in target mRNAs are
well conserved evolutionarily, supporting the regulatory importance of these
interactions70.
Prevailing data suggest the transfer of functional EV-derived miRs from EV producer
cells to recipient cells, with a variety of downstream effects on different molecular and
physiological functions and disease models. Liu et al. showed that miR-193b is released in
the central nervous system via EV and reduces the accumulation of amyloid precursor
protein in neuronal cells thus functioning in the development of Alzheimer s disease

(AD)72. miR-193b can be used as a novel, non-invasive biomarker for AD72. In another
study, neuron-derived EVs were loaded with miR-124a and shown to modulate synaptic
transmission by miR-124a-specific targeting of the glutamate transporter GLT1 in
astrocytes73. As another example, miR-19 content in astrocyte-derived EV induces
downregulation of tumor Pten, promoting brain metastasis 74. In the context of
inflammatory response, miR-155 and miR-146a are released from dendritic cells via EVs
and shuttled between immune cells to regulate cellular response to endotoxin. MiR-155
enhances while miR-146a reduces endotoxin-induced inflammation75. Examples of
functional transfer of miRNAs by EV in mammalian cells are summarized in Table 1.
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Sorting Mechanisms of MicroRNAs into EV
Multiple mechanisms for selective sorting miRNA into EV have been discovered,
including different affinity for membrane lipids, interaction with RNA binding proteins
(RBPs) with specific RNA sequence motifs, and RNA post-transcriptional modifications. The
neutral sphingomyelinase 2 (nSMase2)-dependent pathway is the first reported
mechanism for RNA sorting76. Blocking or overexpressing nSMase2, a hydrolase that
regulates the biosynthesis of ceramide, leads to altered levels of EV-derived miRNAs
including miR-16 and miR-146a76. miRNAs can be loaded into EVs by RNA-RBP interaction.
One of these RBPs is Argonaute 2 (Ago2), a component of RNA induced silencing complex
(RISC). Ago2 has been implicated in controlling secretion into EV of certain miRNAs
including let-7a miRNA, miR-100 and miR320a into EV through the KRAS-MeRK-ERK
signaling pathway77. Similarly, Y-Box binding protein 1 (YBX-1)78 and La protein79 are
other RBPs that can interact with miR-223/miR-133 for the former and miR-122 for the
latter through specific RNA binding protein-RNA interactions. Other studies have reported
that sequence motif-dependent RNA-RBP interaction is involved. The SUMOylated form of
heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) has been shown to direct
the sorting of a group of miRNAs that has a specific short motif GGAG (EXO motif) into
primary T lymphoblast-derived EVs. Removing the EXO motif from EV-enriched miRNAs or
adding the EXO motif into cell- retained miRNAs significantly changed the ratio of the miR
levels in EV to producer cells.

Table 1. Functional Transfer of miRNAs by EV in Mammalian Cells
Disease condition
Rhabdomyosarcoma

Model
In vitro, in
vivo, mice

Donor cells

miRNA

Acceptor cells

Myoblast

miR-486-5p

Fibroblast, myoblast

Breast cancer

In vitro, in
vivo, mice

Breast cancer cells

miR-9, miR-195,
miR-203

Endothelial cells,
epithelial cells, breast
cancer cells

Glioblastoma

In vitro, in
vivo, mice

Glioma cells

miR-9, miR-21

Microglia, brain
endothelial cells

Cardiovascular
diseases

In vitro, in
vivo, mice

Cardiac stem cells

Myocardial
infarction

In vitro, in
vivo, mice

Bone marrow MSC

Muscle injury
Middle cerebral
artery occlusion
Hepatocellular
carcinoma
Liver fibrosis
Skull defect
Neurodegenerative
disorder
Insulin resistance
Lipodystrophy and
obesity

In vitro, in
vivo, rat
In vitro, in
vivo, rat
In vitro, in
vivo, mice
In vitro, in
vivo, mice
In vitro, in
vivo, rat
In vitro
In vitro, in
vivo, mice
In vitro, in
vivo, mice

miR-21, miR-132,
miR-210, miR-451,
miR-146a
miR-21, miR-22,
miR-let7, miR-29,
miR-24, miR-34,
miR-130, miR-378

Various cell types

Biological effects
Cell migration, invasion,
colony formation
Tumorigenesis,
angiogenesis, cell invasion,
cell proliferation, drug
resistance
Angiogenesis,
immunosuppression
Apoptosis inhibition,
angiogenesis, myocardial
fibrosis

Various cell types

Apoptosis and autophagy
inhibition, angiogenesis,
immunosuppression

Ref.
80

81

82

83

17; 84; 85

Bone marrow MSC

miR-494

Myoblast

Skeletal muscle
regeneration, angiogenesis

Bone marrow MSC

miR-133b

Neural cells

Neurite outgrowth

87

Adipose MSC

miR-122

Hepatocellular
carcinoma

Cell cycle and growth

88

Adipose MSC

miR-181-5p

Liver cells

Apoptosis autophagy

89

Adipose MSC

miR-375

Bone marrow MSC

Osteogenic differentiation,
bone regeneration

Neural precursor cells

miR-21

Neural progenitor
cells

Neurogenesis

91

Adipose macrophage

miR-155

Liver and muscle cells

Insulin sensitivity

92

Adipocytes from brown
adipose tissue

miR-99b

Liver cells

Glucose tolerance

93

86

90
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Altering hnRNPA2B1 expression or its sumoylation resulted in changes of EXO miRNAs
levels94. Using a similar approach, Santangelo et al. found that hnRNPQ (SYNCRIP) was
found to bind miRNAs harboring a GCUG common sequence (hEXO motif) that are
selectively sorted into hepatocyte-derived EVs. Silencing hnRNPQ with shRNA led to a
significant reduction of several EV-enriched miRNAs, while insertion of an hEXO motif into
an intracellular miRNA increased its sorting into EVs 95 Finally the

end post-

transcriptional modification of miRNA sequences mediates their relative abundance in
parent cells vs. EV96 The uridylation of the
of miRNA isoforms into EVs whereas

-ends of miRNA enhances the selective sorting

-end adenylated miRNA isoforms are highly

retained in producer B-cells. In summary, specific enzymes or proteins can direct miRNA
sorting into EVs, and certain miRNAs with specific sequences can be selectively sorted to
EVs in certain producer cell types.
Significance of Extracellular Vesicles
Canonically, cells often communicate directly with adjacent cells through gap
junctions and cell surface receptor/ligand interactions. Communication with distant cells
occurs through molecules including proteins, lipids or nucleotides that are released by cells
and bind to receptors on the target cells. Such paracrine signalings are important for cellcell communications in normal/pathological conditions. Emerging data has proven that EVs
can deliver functional molecules, including proteins, transmembrane receptors, lipids,
messenger RNA (mRNA) and non-coding RNA (ncRNA) and so modulate phenotypic
features and responses of recipient cells. The bioactive cargoes in EVs can impact recipient
cells via direct interaction with surface-bound ligands, by transfer of activated receptors or
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by release/delivery of functional proteins, lipids, and/or nucleic acids to recipient cells. In
fact, multiple studies have demonstrated that EVs play important roles in dissemination
metastasis of cancer cells and tumor progression. Specifically, EVs from cancer cells can
change cell motility by targeting extracellular matrix97, and can promote drug resistance63,
tumor angiogenesis 98, and metastasis of tumor cells 99. Tumor-secreted EVs can promote
cancer progression by targeting immune cells. In one study, EVs derived from epithelial
ovarian cancer induced macrophage M2 polarization100. This phenotype is mediated by
miR-940 content in the EVs, leading to metastasis and low survival rates100. Several cancer
cells can transform local fibroblasts into cancer-associated fibroblasts through the
transmission of hTERT mRNA via EVs 101. These transformed fibroblasts in turn can modify
cellular metabolism, enhance glycolysis, and reduce oxidative phosphorylation 102. On the
other hand, immune cells release EVs that target cancer cells. Natural killer (NK) cellderived EV shows antitumor effects against melanoma cells with minimal side effects on
normal human kidney cells. The cytotoxicity is modulated by Fas ligand and perforin
expressed in NK-derived EVs103.
Beside cancer, EV can serve as a mediator in the spread of disease. The presence of
neurodegenerative disease-related EV cargo proteins such as A

tau in Alzheimer s

disease104; 105, alpha-synuclein in Parkinson s disease106 or prion in infectious prion

disease107 supports that EVs represent an important means of intercellular cross-talk in

physiologic and pathologic conditions.
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Stem Cells and -based Extracellular Vesicles Therapy for Myocardial Infarction
Stem cell biology is one of the newest and fastest growing areas in life science. Based
on their proliferation capacity, stem cells can be divided into pluripotent cells (including
embryonic stem cell (ESC), inducible pluripotent stem cells (iPSC)), and multipotent cells
with limited potential (such as cardiac progenitor cells (CPC), cardiosphere-derived stem
cells (CDC), and bone marrow stem cells (MSC))108.
The heart is one of the most attractive solid organs for regenerative medicine as loss
of cardiac cells underlies much of the morbidity and mortality of heart disease. The
rationale of these early studies is based on the regenerative capacity of stem cells to
differentiate into different types of cells and tissues. Indeed, stem cell-based therapy has
been studied to support the reparative process of cardiac tissue and to improve the
function of damaged myocardium in cardiovascular diseases for several decades 109.
Human-derived Embryonic Stem Cells (hESC) or allogeneic iPSC are promising
sources for direct cell replacement of damaged myocardium due to their unlimited selfrenewable capacity and indisputable ability to differentiate into cardiomyocytes 108.
Cardiomyocytes derived from hESC- and iPSC have similar cardiac gene expression
patterns, as well as cardiac specific sarcomeric proteins and ion channels. These cells
display functional properties of cardiomyocytes in regard to electric activity, excitationcontraction coupling and neurohormonal signaling 108. Importantly, they have been
demonstrated to survive in the long term post-transplantation, grow and regenerate
infarcted myocardium in primate models 72; 110. Improvement in cardiac function (ejection
fraction, fractional shortening) is associated with partial remuscularization of the scar by
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grafted cardiomyocytes. However, concerns over the post-transplant arrhythmias and
teratomas formation remain and require more effort to control these unwanted side effects
before clinical application of pluripotent stem cells 72. More recently, new evidence
suggested that iPSC-derived EV can recapitulate beneficial effects of their parent cells for
heart repair111. ESC (iPSC)-EV represents a potentially therapeutic alternative in treating
CVD while circumvent some ethical concerns related to pluripotent stem cells research.
With other multipotent stem cells, the idea that some of these stem cells can
transdifferentiate into new cardiomyocytes and blood vessels, thereby replacing dead
myocardium is one of the biggest controversies in the field. The trans-differentiation
hypothesis was first proposed in 2001 with c-kit+, lineage negative (Lin-) bone marrow
cells112. Newly formed myocardium was reported to occupy 68% of the infarcted ventricle
after transplanting the bone marrow cells 112. Based on these results, a variety of clinical
studies were run with various bone marrow-derived stem cell types, but there was no
significant benefits found113; 114. The improvements found in preclinical and studies were
judged to be due to paracrine effects and transdifferentiation did not occur 115; 116. For
example, study using reporter transgenes to monitor transdifferentiation events showed
no transdifferentiation of haematopoietic stem cells (HSC) into cardiomyocytes in both
normal and injured adult mouse hearts 115. Later murine studies using CPC and CDC also
claimed evidence of transdifferentiation and repair 117, but it was later found that these cells
do not contribute to differentiation of cardiomyocytes118. In one study, cardiosphere CDCderived EV can reproduce the functional effects of CDC transplantation in suppressing
apoptosis, enhancing angiogenesis while inhibition of EV production by CDC attenuated

those

benefits19.
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Further investigation suggested that miR-146a may contribute to some of

the therapeutic benefits of CDC-derived EV19. Besides EV, CDC released several growth
factors including vascular endothelial growth factor (VEGF), hepatocyte growth factor
(HGF), and insulin-like growth factor (IGF-1) that are able to exert cardioprotective
properties.
Overall, the consensus today is that there are no cardiac-resident stem cells and that
circulating stem cells, including MSC do not regenerate myocardium. Beneficial effects,
though small, are reparative and are thought to be due to paracrine mechanisms 119. We
now believe that some of the results reported for stem cell repair are due to these
paracrine protective and reparative effects combined with difficulties distinguishing cell
fusion from division, and salvage from regeneration.
Bone marrow-derived Stromal Cells
Mesenchymal stem cells (MSC) are multipotent stem cells obtained from bone
marrow, adipose tissues and umbilical cord tissue120. To address inconsistencies in tissue
sources and cell preparation methods, the Mesenchymal and Tissue Stem Cell Committee of
the International Society for Cellular Therapy proposes three criteria defining MSC based
on their characteristics, consisting of (1) being adherent to plastic in standard culture
conditions (2) expressing positive surface markers including CD105, CD73 and Cd90 while
not expressing negative surface markers including CD

CD

CD

CD

b CD

and

HLA class II (3) being able to differentiate to osteoblasts, adipocytes, chondroblasts under
standard in vitro differentiating conditions 121.
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Among different types of stem cells employed in stem cell based therapy for the
treatment of I/R injury, MSC were seen as promising candidates due to ease of isolation,
low immune response and safety profile109; 122. MSC can escape immune rejection due to
low expression of HLA and co-stimulatory molecules, making them somewhat immune
privileged120. Furthermore, several early-phase I clinical trials such as Transendocardial
Autologous Cells in Ischemic Heart Failure Trial (TAC-HFT) 123 and Percutaneous Stem Cell
Injection Delivery Effects On Neomyogenesis in Dilated Cardiomyopathy (POSEIDON) 124
have demonstrated good safety profiles for MSC based cell therapies, which are still being
investigated to this day for a variety of diseases and injuries. MSC have been demonstrated
to facilitate tissue repair of ischemic tissue. This effect is associated with reduction in
apoptosis in the border zone and improvement of cardiac function measured by left
ventricular ejection fraction (LVEF) in animal model125; 126. In human clinical trials, MSC
injection shows a modest improvement in ejection fraction of recipient hearts 124; 127; 128.
Report of adult human bone marrow-derived cells transdifferentiating into cardiomyocytes
prompted considerable interest in MSC129. However, as mentioned above, subsequent
studies has shown definitively that MSC do not transdifferentiate into cardiomyocytes. Less
than 1% of transplanted MSC were able to home and engraft in target tissues130. Therefore,
MSC probably exert their effects via paracrine mechanisms through the release of
extracellular vesicles and cytokines.
MSC-derived EV in Cardiac Repair
Many of the studies that attributed to stem cells, including MSC, the ability to
regenerate new cardiomyocytes by trans-differentiation, failed to delineate effects upon
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salvage of myocardium from growth of new muscle. In fact, implantation of MSC has been
shown to elicit cardioprotective effects against cell death after acute ischemia/reperfusion.
The possibility of using MSC-EV to reduce damage after myocardial infarction has been
widely evaluated. Indeed, numerous studies have reported that MSC-derived EVs
recapitulates many of the tissue-healing effects of MSC in in vitro assays and in vivo models.
The first evidence for the beneficial effect of paracrine effects on the heart was reported
by Gnecchi et al131. They discovered that injection of conditioned medium from
mesenchymal stem cell (MSC) cultures overexpressing anti-apoptotic protein Akt1 showed
cardioprotection in both cell culture and murine models of MI. The cardioprotective effect
of the conditioned medium of the overexpression Akt1-MSC induces secretion of frizzled
related protein 2 (Sfrp2), a modulator of Wnt signaling to upregulate -catenin and other
antiapoptotic genes. Silencing Sfrp2 in Akt-overexpressed MSC abrogates the protective

effect of the condition medium132. In 2010, Lai et al. was the first group to isolate and report
cytoprotection of MSC-EV in reducing the infarct size in an animal model for myocardial
I/R injury18. EVs derived from conditioned culture media of MSC have similar size,
morphological features and common surface markers as other cell types, including CD81
and CD9. They also harbor adhesion molecules expressed on the MSC membrane, including
CD44, CD29 and CD73133. EV contain the metabolic enzyme glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) which can supply depleted ATP-producing glycolytic enzymes
after ischemic injury. Furthermore, heat shock protein HSP70 and antioxidant enzymes
such as glutathione S-transferase in the EV cargo can reduce damage induced by protein
aggregation and oxidative stress 134.
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MSC-derived EV Suppresses Apoptosis
Apoptosis is defined as energy-dependent programmed cell death when the cellular
damage is beyond the repair process. Apoptosis is characterized by blebbed membrane,
shrinked organelles, and fragmented, condensed DNA, resulting in release of apoptotic
bodies to be internalized by phagocytes. In addition to necrosis, apoptosis plays an
important role in I/R injury-induced cell death of cardiomyocytes, which eventually leads
to heart failure135. Therefore, many strategies have been developed to block apoptosis in
I/R injury, including MSC-derived EV. This approach has been shown to successfully reduce
reperfusion-mediated apoptosis and improve cardiac function in animal studies.
Evidence suggests that MSC-EV-mediated anti-apoptotic effects are exerted by miRNAs
cargo content. Among anti-apoptotic miRNAs in MSC-derived EV, miR-21-5p is highly
enriched in both parental cells and EV. Transfer of miR-21-5p from EV secreted by human
endometrium-derived MSC promotes myocardial salvage and enhances cardiac function
after MI in a rat model. MiR-21-5p mediates these paracrine actions by modulating the
Pten/PI3K/Akt pathway136. One study also found higher levels of miR-21-5p in EV released
from MSC under oxidative stress than EV collected from MSC under normal conditions.
Exosomal miR-21-5p inhibits Pten expression in C-kit+ cardiac stem cells, leading to
cytoprotection against apoptosis triggered by oxidative stress 137. In agreement with these
results, our group reported the cardioprotective activity of MSC-derived EV using cell
culture and mouse model for I/R injury through miR-21-5p delivery. In this case, these EV
reduce cardiomyocyte necrosis, apoptosis and autophagy by inhibiting FasL, Pten, Beclin1,
PDCD417. Likewise, Wang et al. demonstrated that EV secrets from bone marrow-derived

27
MSC (BMSC) reduce apoptosis and production of ROS in cardiac stem cells (CSC). Under
hypoxic condition EV collected from BMSC have higher protective effects than those
cultured under normoxic condition. Hypoxia also increases miR-214 expression in BMSCderived EV, which is transferred into CSC and suppresses CaMKII involved in oxidative
stress-induced apoptosis and Ca2+ homeostasis138. The effect of hypoxic preconditioning on
MSC-derived EV is confirmed in other studies, which miR-210139 and miR-125b140 in
hypoxia conditioned MSC-EV increase cell survival and reduce infarct size post-MI.
Interestingly, EV derived from senescent MSC have weak activities in inhibiting apoptosis,
promoting angiogenesis and reducing fibrosis. RNA sequencing revealed that miR-221-3p
level is decreased in aged MSC-derived EV, compared to young ones. Overexpressed miR221-3p enhanced pro-survival Akt pathway, increased proangiogenic VEGF, while downregulated Pten and pro-apoptotic protein cleaved-caspase-3141.
Furthermore, long non-coding RNA (lncRNA) in the cargo of MSC-EV also regulates
apoptosis. EV isolated from macrophage migration inhibitory factor is enriched with
lncRNA-NEAT1, which inhibits expression of miR-142-3p and activates Forkhead Box O1
(FOXO1) signaling pathway142. MiR-142-3p has been reported to inhibit survival and
growth pathways whereas loss of miR-142-3p preserves cardiac function during adaptive
hypertrophy. Therefore, lncRNA-NEAT-1/miR-142-3p/FOXO1 represents a novel cellular
RNA signaling pathway in cardioprotection 143.
MSC-derived EV Reduces Inflammation
After initial cardiac injury, cardiac macrophages are recruited and accumulate to
promote repair through crosstalk with other cardiac cells, including fibroblasts and
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endothelial cells. This can lead to myocardial salvage after reperfusion, but it can also
trigger a hyper-inflammatory reperfusion injury-associated response, which is mediated by
immune cells such as neutrophils and macrophages. Striking a balance between optimizing
pro-reparative macrophages and suppressing maladaptive immune cells is the key to
promoting optimal healing144. Evidence for immunomodulatory properties of MSC-derived
EVs as a treatment in acute MI has recently emerged. It has been documented that MSC-EVs
have anti-inflammatory effects by limiting the infiltration and proliferation of CD3+ T cells
and enhancing them to secret anti-inflammatory cytokines such as IL-10 and TGF- into the

infarcted myocardium145. MSC-EVs also suppress B-cell proliferation and differentiation146.
Several studies support that miRNAs in MSC-EVs contribute to their anti-inflammatory
effects. In one study, administration of MSC-EVs alleviated inflammation and reduced
infarct size after myocardial I/R in a mouse model. The efficacy of MSC-EV was dependent
on the interaction of its transfer of miR-182 from MSC-EVs with to macrophages. MiR-182
mediates the capacity to switch between M1 and M2 macrophages through targeting toll-

like receptor 4 (TLR4)/NF- B P) K AKT signaling pathway147. Similar results showed that
EVs derived from adipose MSCs (AMSCs) induces an anti-inflammatory M2 macrophages
phenotype. This effect is mediated via transferring of a group of upregulated miRNAs in
AMSC-EVs, including miR-21, mir-34a-5p, and miR-146a-5p148.
In addition to miRNAs, protein cargo of MSC-EVs can regulate the immune response.
A significant amount of regulatory factors for inducing immune tolerance are detected in
MSC-EVs, including programmed death ligand-1 (PD-L1), galectin-1 and TGF-

149.

PD-L1 is

an essential component of the PD-1/PD-L1 pathway in T cell receptor (TCR) signaling, thus
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reducing glucose metabolism and cytokine synthesis, and blocking proliferation and
survival of T-cell150. Galectin-1 is a negative regulator for both innate and adaptive immune
response, inhibiting cell growth, and promoting apoptosis of activated immune cells 151. On
the other hand, TGF- function in immune response is context-dependent to stimulate

either pro- or anti-inflammatory pathways152. These findings shed a new light on using
MSC-derived EV as novel therapies for myocardial injury.
MSC-derived EV Enhances Angiogenesis
Angiogenesis is the formation of new blood vessels from pre-existing vasculature.

After the onset of MI, adequate angiogenesis salvages infarcted myocardium through
necessary perfusion of oxygen, and nutrients, preventing cell death, expansion of infarct
and dilation of the left ventricular. In contrast, poor angiogenesis causes hypoperfusion of
viable myocardium, promotes apoptosis and dysfunction of cardiomyocytes, leading to
decreased contractile function and heart failure153. Therefore developing efficient proangiogenic therapeutics represents a promising strategy for treatment of acute MI. Indeed,
several studies have shown MSC-derived EV stimulate angiogenesis in target cells.
Treatment with MSC-EV upregulates expression of a number of pro-angiogenic and
angiogenesis-associated factors, such as vascular endothelial growth factor (VEGF), proangiogenic fibroblast growth factor-

FGF-

in cardiac cells154.

Evidence suggests that MSC-EV elicit pro-angiogenic effects via vesicle-bound
vesicle- protein cargo. In one study, MSC-derived EVs have abundant levels of VEGF, matrix
metalloprotease-9 (MMP-9), and extracellular matrix metalloprotease inducer (EMMPRIN),
whose role in stimulating angiogenesis has been reported 155. Knocking down EMMPRIN
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causes loss of EMMPRIn in EVs and reduces the ability of MSC-EVs to stimulate
angiogenesis both in vitro and in vivo. Proteomic analysis of MSC-EVs from another study
revealed the presence of pro-angiogenic factors including transforming growth factor(TGF-

VEGF platelet-derived growth factor (PDGF), interleukin-8 (IL-8)156, adhesion

proteins associated with endothelial cell proliferation and angiogenesis including ezrin,
galectin-1, p195157, and nuclear factor-kappaB (NF- B signaling pathway proteins158.
In addition to protein cargo, MSC-EVs mediate pro-angiogenic effects through direct

transfer of their miRNA contents. Mayourian et al. demonstrated that treatment with miR21-5p contained in human MSC-EVs increased expression of proangiogenic factors VEGFTGF- angiopoietin-1 via the PI3K signaling cascade in cardiomyocytes 159. In another
study, Ferguson et al. profiled the miRNA content of MSC-derived EV and identified

biological processes modulated by exosomal miRNAs. They found the top EV enriched
miRNAs (miR-21-5p, miR-23a-3p, and miR-1246) are predicted to target angiogenesis and
tissue remodeling pathways including TGF- signaling PDGF signaling and Wnt signaling
This network analysis was confirmed by the upregulation of mRNA for mediator of

angiogenesis genes (ephrin type-B receptor 2 (EPHB2), and neuropilin 2 (NRP2)) and proangiogenesis genes (angiopoietin-1 (ANGPT1), ANGPT4, and ANGPTL4) in HUVEC treated
with MSC-EV. Furthermore MSC-EV loaded miR-130a-3p showed angiogenic effects
through targeting the antiangiogenic protein HOXA5 160. Taken together, these studies
suggest involvement of MSC-derived EV in angiogenesis post MI.
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Clinical Trials Involving MSC-derived EV
Currently, the lack of standards for cell culture conditions, as well as optimal
protocols for production, isolation, storage underlies much batch-to-batch variation of EV
products. Additional criteria to determine therapeutic dose, administration regime and
reliable assays to assess miRNA transfer and efficacy are needed to facilitate the use of
MSC-derived EVs in the clinical setting161. However there are several ongoing trials to
evaluate the safety and therapeutic efficacy of MSC-derived EVs in patients. Some published
clinical studies show encouraging results. In one study, treatment with MSC-EVs reduced
the production of pro-inflammatory cytokines )L

TNF and )FN from peripheral blood

mononuclear cells in patients with severe forms of graft-versus-host disease (GVHD)162. In

another study, the administration of umbilical cord MSC-derived EVs improved the kidney
function in chronic kidney diseases as assessed by improvement of glomerular filtration
rate, serum creatinine levels and reduction of inflammation 163.
In conclusion, numerous studies have shown the therapeutic efficacy of MSC-derived EVs
and their potential for human clinical trials. The purpose of this study is to elucidate the
mechanisms by which MSC EVs exert therapeutic effects and to improve these effects in
models of IR injury.
Summary of Goals and Hypothesis
Myocardial infarction is the one of the leading causes of CVD death worldwide 164. In
MI, occlusion of coronary arteries results in insufficient blood supply to myocardial cells.
Subsequently, there is an imbalance between oxygen supply and demand, reduced ATP
levels, increased influx of calcium. Together, these adverse events trigger cell death.
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Reperfusion is necessary to reestablish blood flow return to the ischemic area, and yet,
reperfusion can do further damage causing irreversible cardiomyocyte loss, namely
ischemia-reperfusion injury4. I/R injury, if untreated, can lead to heart failure and death.
Therefore, finding new therapeutics to reduce damage after MI is desperately needed 4; 7; 164.
EV-associated miRNA cargoes have been shown to be preferentially enriched in EV and to
be functional in the target cells 165; 166; 167. However, the sorting mechanism and the cellular
functions of specific MSC-derived EV associated miRNA have yet to be resolved,
particularly in their relationship to CVD therapy. We propose that EV and specific miRNAs
are critical mediators of the beneficial effects of transplanted MSC in the heart. Our lab
finding that some of the protective effect of MSC-derived EV may still persist after removal
of miR-21-5p17, suggests there must be other protective exosomal miRNAs whose functions
in I/R injury have not previously been studied. Our discovery that a specific group of
miRNAs are selectively sorted into MSC-EV provides a jumping off point to investigate the
contribution of these miRs to cardioprotection in the heart. Therefore the central
hypothesis for this dissertation is that RNA-binding proteins are involved in the selective
transport of miRNAs containing specific RNA-sorting sequences into extracellular vesicles
to exert protective effects against ischemia/reperfusion injury. This hypothesis was tested
by pursuing the following two aims.
Aim 1. Determine the Mechanism of Selective Sorting of miRNAs into MSC-derived EV
The microRNA content of EV is important for intercellular communication 168. During
EV biogenesis, mRNA/ncRNA can be loaded via passive transport or via active sorting
mechanisms169. Passive loading of miRNA such as miR-21-5p relies on mass action effect,

33
whereas active EV sorting involves the recognition of specific

sequences 94; 95

or post-

translational modifications of ncRNA170. Our preliminary data indicates the relative
abundance of specific miRNAs is not the same in parent cells and EV. Several miRNAs such
as miR-486-5p, miR-122-5p and miR-451a were detected at relative high levels in EV
relative to producer cells, suggesting the loading of exosomally enriched MSC miRNAs is an
active and selective process. The objective of Aim 1 is to identify key components of the
miRNA selective sorting apparatus which control the sorting of enriched exosomal nucleic
acids.
Aim 2. Examine the Protective Effects of Selectively Sorted EV miRNA against myocardial
I/R injury.
MSC-derived EV have demonstrated the ability to ameliorate tissue injury via their miRNA
and protein cargoes18; 171; 172. Our lab recent study indicated that miR-21-5p is a key factor
behind the protective effect of MSC derived EV due to the suppression of PDCD4, Pten, Peli1
and FasL17. We observed a significant protection after injection of wild-type EV, compared
to saline group. Pre-treatment with miR-21-5p-depleted EV produced a small but not
significant reduction of infarct size, suggesting other EV cargo may also contribute into the
cardioprotection. Our preliminary study shows that miR-486-5p, the top enriched EV
miRNA targets pro-apoptotic protein PDCD4 in vitro. Therefore, the objective of Aim 2 is to
identify cytoprotective effects of EV-selectively sorted miRNAs, with a focus on miR-4865p.
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Innovation and Significance
These studies are novel and innovative in that their findings shed light on MSC EVassociated non-coding RNA secretome. A mechanistic understanding of exosomal miRNAsorting as well as the function of specific miRNAs will allow possible selective modification
of exosomal miRNA cargo which, in turn, opens the way for development of cell-free
molecular therapeutic approaches for damage-associated with ischemia reperfusion injury.

CHAPTER II
MATERIALS AND METHODS
Animal
B6.129 mice (8-10 weeks) were purchased from Jackson labs (#002609) and were
maintained per NIH guidelines in the Guide for the Care and Use of Laboratory Animals 173
and animal protocol approved by Institutional Animal Care and Use Committee at Loyola
University Chicago (LU permit number 206610). Upon arrival, mice were acclimated for
seven days prior to any procedures. Mice were housed in a group of two and had accessed
to food and water ad libitum. Animals were kept on a standard 12:12 light/dark cycle. All
procedures and techniques using animals were performed by qualified researchers. All
efforts were made to minimize animal suffering.
Ischemia/Reperfusion Injury
We used an in vivo model for occlusion of left anterior descending (LAD) coronary
artery to induce I/R injury as described174. Mice were anesthetized with sodium
pentobarbital (90 mg/kg, intraperitoneal injection). Respiratory rate was maintained at
100±5/min. using a mini-ventilator (Harvard Apparatus). The heart was accessed by lateral
thoracotomy between the 2nd and 3rd ribs. LAD artery was tighten with a 8-0 nylon suture
at the position 2-4 mm from the tip of the left atrial appendage, and was occluded for 45
min., followed by reperfusion overnight. Successful myocardial ischemia and reperfusion
were monitored by widening of the QRS complex, T wave inversion, and ST segment and
35
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reversal of those

changes174.

Animal temperature was monitored with rectal probe

thermometer and was maintained at 33.5-36.5oC by a heating pad throughout the
procedure. We excluded mice from the experiment if we observed no change in ST interval,
or inconsistent change during ischemia phase, or no reversal of the ST-elevation
throughout reperfusion phase.
Infarct Size Assessment
Mice were sacrificed 24 hours after in vivo I/R injury by sodium pentobarbital
overdose as described previously174. The heart was perfused with 1% triphenyltetrazolium
chloride (TTC) in PBS via the aorta. Then the areas of the heart not at risk was stained by
perfusing with a 5% phthalo blue dye in PBS (Heucotech, # 515303) while the suture
around the LAD was still secured. TTC is a redox indicator that turns from colorless to red
by living cells, whereas dead cells remain white. Then the hearts were partially frozen at 20oC and sliced into 4-5 1mm pieces, weighted and imaged with a Nikon camera. The viable,
dead, and area not at risk regions were quantified with NIH Image J. The percent area at
risk was calculated as described previously 175.
Cell Culture and Extracellular Vesicles Isolation
MSC were isolated from bone marrow and bone chips of femur and tibia of female
B6.129 mice (8-10 weeks). The isolation and expansion of MSC were performed as
previously described17. Briefly, muscle and connective tissue were cleansed from the bone.
After the tip of the bones were clipped, the marrow was flushed from the bone with a 21gauge needle into isolation medium consisting of RPMI-1640 (Fisher, # 11875093) with
10% Fetal Bovine Serum (FBS) (Gibco, #10082147), 10% horse serum (HS) (Gibco, #

37
16050122), 100U/ml penicillin, 100 µg/ml streptomycin (ThermoFisher, #15140122) and
12 µM L-glutamine (ThermoFisher, #25030149). After all bones had been flushed,
suspension was filtered through a 70 µm cell strainer, and plated into T-75 flask. After 24
hour, cells were rinsed with PBS to remove non-adherent cells and new isolation medium
was added. This process was repeated for two weeks until cells reached 80% confluent.
Cells were lifted with 0.25% Trypsin-EDTA (ThermoFisher, #25200056) and plated into a
new T-75 flask (passage 1). Cells that did not lift were discarded. After isolation 2-4 weeks,
MSC were expanded with Iscove modified Dulbecco medium (IMDM) (ThermoFisher,
#31980030) containing 10% exosome-free FBS, 10% exosome-free HS, 100 U/ml penicillin,
100 µg/ml streptomycin and 12 µM L-glutamine. At passage 5th, expression of surface
marker of MSCs such as D44, CD29 and Sca1 was confirmed with flow cytometry (Table 2
and Fig. 1). H9c2 cells (ATCC) were maintained in Dulbecco's Modified Eagle Medium
(DMEM) (ThermoFisher, # 12430054) supplemented with 10% FBS.
Table 1. Antibodies Used in Flow Cytometry Experiment
Amount/106
cells
CD29 - Phycoerythrin
1µl
MSC
CD44 - Allophycocyanin
1µl
Sca-1 - Pacific BlueTM
5µl
Hematopoietic stem cell
CD45 - Phycoerythrin-Cy7
1µl
Leucocyte
CD11b - Brilliant VioletTM
5µl
EVs were then isolated by ultracentrifugation at 100,000xg for 70 min. EV pellet was
Cell types

Antibody-fluorophore

resuspended in 500µl PBS and subjected to clean up step at 100,000xg for 70 min. one
additional time. 200 µl PBS was used to re-suspend the final EV pellets. EV samples were
stored at -80oC for subsequent analysis.
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Figure 1. Surface Markers of MSCs. Wild-type MSC of passage 5 were detached with
Accutase (Stemcell, # AT104) and stained with fluorescently conjugated primary
antibodies for CD29, CD44, Sca-1, CD45 and CD11b (red line). Negative controls were
unlabeled cells (cyan line). A shift to the right indicates the present of the antigen in the
cells.

Small RNA Sequencing of miRNAs
Small RNA sequencing was carried on: miRNA from MSCs (N=4), MSC EV (N=3),
hnRNPA2B1 KO EV (N=3), Cas9 EV (N=3). Illumina library prep and sequencing were
completed by the Loyola Genomic Facility for MSC and EV and by Northwestern University
Genomic Facility for hnRNPA2B1 KO EV and Cas9 EV. Analysis on differential expression of
MSC and EVs were performed by Dr. Yutao Liu at Augusta University, Georgia. The RNA
concentrations were measured using the Qubit 2.0 Fluorometer (Invitrogen) while quality
was evaluated using the RNA6000 Nano chip on the Agilent 2100 Bioanalyzer (Agilent
Technologies).
Small RNA Libraries Generation and Sequencing.
NEBNext Multiplex Small RNA Library Prep Kit for Illumina was used to prepare
template libraries cDNA from total RNA of MSCs (N=4) and EV (N=3, one failed quality
control) and TruSeq Small RNA library prep kit (Illumina) for total RNA of EV from
hnRNPA2B1 KO and Cas9 as described previously17. The libraries (N=3-4) were then
analyzed using Illumina Hiseq 2000 instruments to yield 50 base pair single end reads . The
sequencing reads, after removing adapters and low quality reads, were aligned to the
mouse genome (GRCm38) using BowTie (v.0.12.8) and analyzed by DESeq. 1.5-fold cutoff
and Benjamini-Hochburg adjusted P
differently between conditions.

were used to analyze miRNAs that expressed
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DAVID and miRNA Targets Prediction
For the Gene Ontology (GO) enrichment analysis, the gene functional classification tool
DAVID (Database for Annotation, Visualization and Integrated Discovery) was utilized to
characterize by GO annotation into two categories: the cellular compartment, and
functional clustering of the mass-spectrometry dataset to annotate biological meaning for
the data176. A corrected P

was considered significant

The targets of miRNA of interest were identified using the DIANA-microT-CDS and
MiRanda targeting algorithm on Targetscan.org(mmu_71)177 and microRNA.org178. We
used PathwayStudio to collect biological pathways that were relevant to cell death
annotated with the terms apoptosis or cell survival or death

Weighted context

score from Targetscan was used to rank miRNA and target protein. Only targets with the
highest negative score were considered for further analysis.
RNA-motif Identification
To identify over-represented sequence motif on EV-enriched miRNA, we employed a webbased tool Multiple Em for Motif Elicitation (MEME) at https://meme-suite.org/meme/179.
Eight EV-enriched miRNAs from small RNA-sequencing that have P-adjusted

and

more than 1000 reads in EV, were used as input sequence. The same criteria were applied
for six cell-retained miRNAs. The zero-or-one occurrences per sequence (ZOOPS) model
was selected to find motifs width of 4-8 bases.
Proteomic Analyses
In-solution digestion was used for protein identification with samples isolated from MSC
and EVs as described previously180. In brief, samples were diluted to 100 mM ammonium
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bicarbonate solution, pH8. DTT was added to the samples to at final concentration of 10mM
and incubated at 55oC for 30 min. Samples were then alkylated with 200mM iodoacetamide.
Samples were digested by incubation at 37oC overnight with trypsin MS grade
(ThermoFisher, #PI90057) 1:25 trypsin to protein (w/w). Digestion was stopped by adding
trifluoroacetic acid to a final concentration of 1%. Samples were desalted using a C18 Omix
Zip Tip for Orbitrap analysis. LC-MS measurements were performed at Proteomic core
facility of Northwestern University.
Transmission Electron Microscope
Negative staining was used to image and assess the morphology of EVs with transmission
electron microscope181 )n brief

for min

l of EV were fixed with ml of

paraformaldehyde

l of the EV suspension was loaded onto a carbon film coated

mesh

copper EM grid , incubated for 1 min, and stained with 1% uranyl acetate for 1 min. The
excess staining solution was removed with filter paper. The images of EV were captured
under a transmission electron microscope (Philips CM120 120kV) after the grids were
dried.
EV Nanosight Experiment
EVs isolated from conditioned medium of wild type MSCs, hnRNPA2B1 KO MSC, Cas9 MSC
control, were diluted in PBS (1:1000 ratios), drawn into a 1 ml syringe,
and loaded into sample chamber of Nanosight NS3000 instrument (Malvern). The particles
were visualized with 20x magnification. The Nanoparticle Tracking Analysis software was
used to quantify the size distribution and concentration of particles in the samples. Each
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sample was measured three times and the counts were averaged. PBS was used as a
baseline for measurement.
HnRNPA2B1 Protection Assay
To confirm the presence of hnRNPA2B1 inside of EV, EV were isolated from 250 ml
conditioned medium, as described above. The pellet after ultracentrifugation steps was
resuspended in 10 µL HBSS or 1% Triton X-100, vortexed, and incubated at room
temperature for 5 min as described previously182. Half of the HBSS-resuspended samples
and Triton X-treated sample were incubated with 5 µl proteinase K solution (20 mg/ml)
(Promega, #S46897). Additionally, 10 µg of WT-MSC cell lysate was treated with 5 µl
proteinase K solution (20 mg/ml) or HBSS. All samples were incubated for 30 min. at 65oC
with proteinase K, followed by 15 min. at 95oC to deactivate the proteinase K.
Subsequently, 15 µl RIPA buffer supplemented with 1:25 100X proteinase inhibitor
(ThermoFisher, #PI88669) was added to the samples. Samples were then prepared for the
Western blot procedure, resolved on a 10% polyacrylamide gel, transferred and
immunoblotted against hnRNPA2B1 and HSP-70.
CRISPR-Cas9 Genome Editing of hnRNPA2B1
Three different guide RNAs (gRNAs) targeting the second exon of hnRNPA2B1 open
reading frame, were designed using Benchling tool (https://www.benchling.com/crispr/).
The design was to remove the second exon and introduce a premature stop codon to
truncate the mRNA and produce a loss-of-function allele. The
gRNAs were phosphorylated, annealed and cloned into lenti-CRISPR v2 backbone vector as
described182. To produce viral particles, gRNA/Cas9 plasmid, viral packaging plasmid NRF
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and viral envelope plasmid VsV-g (5µg each) were co-transfected into packaging 293T
cells with LipofectamineTM 3000 (Thermo Scientific, #L3000015) according to
manufacturer s instructions In brief, 5µg of each construct (15 µg total DNA) was diluted in
500µl of OptiMEM, while 40µl of P3000 reagent was added into diluted DNA and mixed

gently. In another tube, 15µl of Lipofectamine3000 was diluted in 500µl of OptiMEM. Then
the diluted DNA was mixed with diluted Lipofectamine in a volume of 1000 µl, and
incubated for 5 min. at room temperature. Transfection complex was added into
designated plates with 10ml of regular medium and placed back in incubator for 6 hours.
The transfection was stopped by removing the medium containing the transfection
complex and adding 10ml of regular medium (see Cell Culture and Extracellular Vesicles
Isolation).
Table 2. List of gRNAs used to target the second exon of hnRNPA2B1 gene
Hnrnpa2b1_Assembly_1_FWD

CAC CGT TCC GAA AGC TCT TTA TTG G

Hnrnpa2b1_Assembly_1_REV

AAA CCC AAT AAA GAG CTT TCG GAA C

Hnrnpa2b1_Assembly_2_FWD

CAC CGA GAA ACT ACT ATG AGC AAT

Hnrnpa2b1_Assembly_2_REV

AAA CAT TGC TCA TAG TAG TTT CTC

Hnrnpa2b1_Assembly_3_FWD

CAC CGA GAA ACT ACT ATG AGC AAT G

Hnrnpa2b1_Assembly_3_REV

AAA CCA TTG CTC ATA GTA GTT TCT C

Plates were left in a 37oC incubator overnight. After 48 hours, supernatant
containing viral particles was collected by centrifugation at 1,000xg for 20 min., and
filtered through 0.45 µm low protein binding filter. The stable MSC lines
expressing gRNAs against hnRNPA2B1 were generated by transduction of WT-
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MSC with 500 µl lentiviral aliquot per well (24 well plates; 10,000
cells/well). Selection with puromycin (4 µg/ml) in complete medium was started 48
hours post transduction and ended after all untransduced MSC (control
plate) died. The polyclonal populations were expanded and tested for the deletion of
hnRNPA2B1 by immunoblot for hnRNPA2B1 (SCBT, # sc-374053).
Nuclear extracts for EMSA and RIP
Nuclear extracts of WT-MSC or hnRNPA2B1 KO-MSC for gel-shift assay were
prepared using NE-PERTM Nuclear and Cytoplasmic Extraction Reagent (ThermoFisher,
#78835). 5 x 106 cells were harvested by trypsinization, and then centrifuged at 500xg for
5 min., washed with PBS before being resuspended in 500 µl of cold Cytoplasmic Extraction
Reagent (CER) I supplemented with 100X protease inhibitor. The suspension was
incubated on ice for 10 min. before 27.5 µl of cold CER II was added and incubated on ice
for 1 min. The cytoplasmic fraction (supernatant) was collected by centrifugation at
16,000xg for 5 min. The pellet (nuclear fraction) was suspended in 100 µl icecold NER supplemented with 100X protease inhibitor (ThermoFisher, #PI88669). The
suspension was incubated on ice, and vortexed for 15 sec. on highest setting every 10
min. for a total of 40 min. The nuclear extract (supernatant) was isolated by centrifugation
at 16,000xg for 10 min. The protein concentration was measured with BCA Protein
Assay (ThermoFisher, # 23225).
To prepare nuclear extract for the immunoprecipitation and biotinylated RNA pulldown assays, WT-MSCs were cultured to reach 80-90% confluent for subcellular
fractionation. Cells were rinsed twice with PBS, trypsinized and collected by centrifugation
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at 1,000 xg for 5 minutes at

4oC.

The cell pellet was rinsed twice with cold PBS,

resuspended in 1 ml of ice-cold cell lysis buffer supplemented with 1 mM DTT, 4U/ml
RNAse inhibitor (ThermoFisher, #AM2682), and 1X protease inhibitor cocktail
(ThermoFisher, #23225), incubated on ice for 10 minutes. The nuclei were collected by
centrifugation at 1,000xg for 5 minutes at 4oC. The nuclei pellet was resuspended with 600
l of ice-cold TSE buffer (0.02 M Tris-HCI, pH 7.8; 0.1 M NaCl; 1 mM EDTA) supplemented

with 1mM DTT, 4U/ml RNAse inhibitor, and 1X protease inhibitor cocktail. The nuclei

lysate was sonicated five times on ice (9 seconds at 0.5 outputs), passed through a 27gauge syringe five times, then incubated on ice for 20 minutes with occasional vortexing
every 10 minutes, followed by a 10 minutes spin at 16,000xg at 4oC. The supernatant was
collected for further experiments. Protein concentration was measured by standard
Bradford assay ThermoFisher
tube labeled as )nput

l

of the nuclei lysate was put in a new

RNA Immunoprecipitation (RIP) Assay

750µg of nuclear lysate was premixed with 10µg anti-hnRNPA2B1-B7 (SCBT, # sc374053) or IgG antibody (Vector, #58421) in RIP buffer and incubated overnight at 4oC.
l

of the lysate was used as an input sample Then

l of washed

Dynabead (ThermoFisher, #14112-89) was mixed with antibody-antigen complex, and
incubated for 2 hours at 4oC. Beads were captured using a magnetic stand (ThermoFisher,
#65002, and washed three times with 500µl cold PBS containing 0.1% Tween-20 detergent.
After the last wash, the beads was incubated at 55oC for 30min with 100µl of PBS
supplemented with 0.5% NP40, 40U/µl RNase inhibitor and 50µg proteinase K. The elutant
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was purified using Qiazol reagent (Qiagen, #79306) and concentration of RNA was
quantified using Nanodrop spectrophotometer. Mature miRNA expression levels were
quantified using miScript SYBR Green PCR Kit (Qiagen, #218073) on AriaMX instrument.
EMSA and Super-shift Assay
The in vitro interaction between miRNA and the proteins in nuclear lysate were
evaluated by electrophoretic gel shift assay (EMSA). The assay was carried out with
LightShift Chemiluminescent RNA EMSA Kit (ThermoFisher, # 20158) according to the
manufacturer s instructions )n brief

g of nuclear lysate was mixed with pmol of

-

biotinylated miRs (mmu-miR-486-5p: UCCUGUACUGAGCUGCCCCGAG-[Btn], mmu-miR122a: UGGAGUGUGACAAUGGUGUUUG-[Btn], mmu-miR-451a:
AAACCGUUACCAUUACUGAGUU-[Btn], mmu-miR-1291a:
UGGCCCUGACUGAAGACCAGCAGU-[Btn]) (Sigma-Aldrich), in a volume of 20µl 10X REMSA
binding buffer supplemented with 2µg tRNA and 5% glycerol, and incubated for 30 min. at
room temperature. The RNA-protein complex was loaded on a 5% native polyacrylamide
gel, and electrophoresed until the bromophenol blue dye had migrated to halfway down
through the gel. The RNA-protein complex was then transferred to a positively charged
0.45 µm nylon membrane (ThermoFisher, # 77016) in 0.5X TBE buffer (0.13 M Tris-HCl
(pH 7.6), 45 mM boric acid, 2.5 mM EDTA) at 300 mA for 45 min. After biotinylated RNAprotein complex was cross-linked using a UV-crosslinker (Boekel Scientific) for 2 min., the
membrane was blocked, washed, equilibrated, and stained with luminol/peroxide- as
described in the manufacturer s protocol ThermoFisher

Chemiluminescent

signal was visualized using a Chemidoc Imager (Biorad). The super-shift assay was
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conducted as described above, with the addition of 1 µg antibody against hnRNPA2B1
(SCBT, # sc-374053).
Biotinylated-RNA Pull-down Assay
1 µg of biotinylated RNA (Sigma-Aldrich, TX) was mixed with 500µl of 500 µg of
nuclear lysate, 100X protease inhibitor (ThermoFisher, # 23225), 40U/µL RNase inhibitor
(ThermoFisher, #AM2682), and 2X TENT buffer (20mM Tris-HCl, 2mM EDTA, 500mM NaCl,
1% Triton X-100), and incubated for 30 min. at room temperature. The RNA-protein
complexes were fixed using a UV-crosslinker (Boekel Scientific) for 10 min, and then mixed
with 50 µl of streptavidin magnetic beads (NEB, #S1420S). The mixture was incubated for
another 30 min. at room temperature. The beads were captured by a magnetic stand
(ThermoFisher, #65002) and washed three times with 1X cold TENT buffer. After the last
wash, the RNA-protein complex was eluted with 40 µl of 1X Laemmli buffer (Bio-Rad,
#161-0474) and incubated at 95oC for 5 min. The elutant were loaded on a 10% SDS-PAGE
gel, separated at 120 mV for 60min., and transferred at 250 mA for 2 hours at 4oC, followed
by Western blot to detect target proteins. The competition assay was carried out as
described above with the addition of 20X excess amount of unlabeled-miRNAs into the
reaction before adding labeled miRNAs.
Simulated Ischemia-Reperfusion
104 H9c2 cells per well were seeded in a 96-well plate and the sim I/R injury model
was established as described before17. Cells were incubated in ischemia mimetic solution
(in mM: 125 NaCl, 8 KCl, 1.2 KH2PO4, 1.25 MgSO4,1.2 CaCl2, 6.25 NaHCO3, 5 sodium lactate,
20 HEPES, pH 6.6 at 37ºC) in a hypoxic chamber (Biospherix) for 12 hours. The oxygen
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level was kept below 0.5% by replacement with nitrogen, while CO2 was kept at 5%. After
12 hours of ischemia, cells were returned to a normoxic incubator for 2 hours and the
ischemia mimetic solution was replaced with complete growth medium. Cell viability was
assessed by incubating cells for 30 min. with Hoechst 33342 solution (0.2 µg/ml)
(ThermoFisher, #H3570) and propidium iodide (PPI) (2µ/ml) (ThermoFisher, #p3566).
The images were captured and analyzed with Cytation 5 Cell Imaging Multi-Mode Reader

(BioTek) using DAPI filter for Hoechst+ to detect all cell, and the Texas Red filter for PPI+ to

detect necrotic cells. The percentage of cell survival was calculated by dividing the number
of viable cells after sim I/R challenge by the number of viable cells before sim I/R.
RNA Isolation
For RNA extracted from cell and extracellular vesicles, Qiazol lysis reagent (Qiagen,
#79306) was added at 1:3 parts sample to Qiazol, incubated for 5 min. at room
temperature. Then 0.2ml of chloroform was added for each 0.25ml Qiazol in the sample.
The samples were vortexed for 15 sec., incubated for 3 min. at room temperature, and spun
at 12,000xg for 15 min. at 4oC. The upper aqueous phase containing RNA was transfer to a
new tube for RNA precipitation with 0.5ml of 100% cold isopropanol per 0.75ml Qiazol
lysis reagent. Samples were incubated at room temperature for 10 min., and then
centrifuged at 12,000xg for 10 min. at 4oC.The supernatants were discarded completely
while RNA pellets were washed with 1ml of 75% ethanol per 0.75ml Qiazol used for initial
homogenization. Samples were vortexed 10-15 sec., centrifuged at 7,500xg for 5 min. at 4oC,
and air dried. The RNA precipitates were resuspended in 15-20µl of RNAse free water and
mixed until the precipitate was no longer visible. to deactivate glycogen. Concentration and
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quality of RNA samples were evaluated with the Nanodrop spectrophotometer. Samples
with 260/280 ratio above 1.8 were used for downstream analyses. RNA samples used for
RNA-sequencing experiments were assessed with the Aligent 2100 Bioanalyzer system.
Reverse Transcription (RT)
For RT of mRNA, 200ng of isolated total RNA was mixed with 10µl 2X RT buffer, 2µl
20X Applied Biosystems RT enzyme mix (ThermoFisher, # 4368813), and RNAse free
water in a volume of 20µl. The thermal profile was set as: 1 hour at 37oC, 5 min. at 95oC,
and held at 4oC. The cDNA product was diluted 10 fold with RNAse free water for
quantitative PCR.
For RT of miRNA, 100ng of total RNA was mixed with 2µl 10X nucleic mix, 4µl 5X HiFlex
buffer, 2µl miScript reverse transcriptase enzyme (Qiagen, #218160) and RNAse-free
water in a volume of 20µl and placed in a thermal cycler under the following condition: 1
hour at 37oC, 5 min. at 95oC, and held at 4oC. The cDNA was diluted in 200µl RNAse free
water.
Quantitative Real Time PCR (qPCR) Analysis
For quantitative analysis of mRNA expression, qPCR was conducted with Applied
Biosystems® SYBR® Green (ThermoFisher, #4309155). A 20µl of reaction mix contained
10µl 2X SYBR Green master mix, 0.25µl forward and reverse primers, 4.5µl RNAse free
water and 5µl template cDNA. ROX dye in 2X SYBR Green master mix was used as passive
reference. PCR was run on an AriaMX instrument with the thermal profile: 15 min. at 95oC
for hot start, denaturing for 15 sec. at 95oC, annealing for 30 sec. between 55oC-60oC
depend on primers, and extending for 30 sec. at 70oC, followed by a melt cure. All reactions
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were performed in triplicate and normalized to 18S using the

2(-

CT

method183.

Primers

for the mRNA of interest were designed using NIH Primer Blast software and ordered from
IDT (Coralville, IA). For real time quantitative PCR of cDNA synthesized from miRNAs, a
reaction of 20µl was consisted of: 2µl 10X miScript primer assay specific to the miRNA of
interest (Qiagen, miR-486-5p #MS00029246, miR-122a #MS00001526, miR-451a #
MS00002408, miR-22a-3p # MSY0000531, miR-1291a # MS00077048, miR-5121a #
MS00043071), 2µl 10X miScript universal primer, 10µl 2X SYBR Green (Qiagen, # 218073),
cDNA product and RNAse-free water. qPCR was carried out for 40 cycles with thermal
cycling: 15 min. at 95oC, denaturing for 15 sec. at 94oC, annealing for 30 sec. at 55oC, and
extending for 30 sec. at 72oC with data collection.
Table 3. List of Primers Used in qPCR for mRNA Expression Levels
PDCD4 total
F

-TACCGCATTTCCACCACGAG-

(R) 5 -GCACAGAGTATGAGTGTGGGACPDCD4 sliced
F

R

-GAAGGAGATGGAGGTCGTCTTAAACC-AGGTGGTTACTCTTCGGTCCCT-

Pten
F

-GGCCAACCGATACTTCTCTCC-

R

-CTGGATCAGAGTCAGTGGTGT-

F

-AGTCCCTGCCCTTTGTACACA-

18S

R

-CCGAGGGCCTCACTAAACC-

All reactions were performed in triplicate and U6 RNA (Qiagen, # MS00033740) was used
as internal control. The relative expression of RNA to internal control was calculated using
the 2(-

CT

method.

For absolute quantification of miRNA, a standard curve of cDNA synthesized with
miScript mimetic miR-486a-5p (Qiagen, #MSY0003130) was used for determination of
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copy number of the miRNA under study. In brief, 5µl of 20µM miScript miRNA mimetic was
used to synthesize cDNA with miScript II RT kit (Qiagen, #218160). The cDNA was diluted
in RNAse-free water to yield 1010copies cDNA/µl. Serial dilution was prepared from the
diluted cDNA and RNAse-free water. 2µl from each dilution (with template copy numbers
in the PCR ranging from 109to 104) was used to set up separate real-time PCR reactions.
Results from the PCR were used to plot a standard curve of CT value against log copy
number of miRNA of interest.
Transfection
H9c2 cells were seeded in 6-well plate to 70-80% confluent and transfected with
either miR-486a-5p mimetic (Qiagen, #MSY0003130) or scrambled non-targeting miRNA
(scramble) served as negative control (Qiagen, #1027280) using LipofectamineTM 2000
(ThermoFisher, #11668019), according to the manufacturer s protocol ThermoFisher

#11668019). In brief, LipofectamineTM 2000 or mimetic of miR-486-5p or scramble was
gently mixed with 250µl of Opti-MEM (Invitrogen, # 11058021) and incubated for 5 min. at
room temperature. The diluted miRNA was combined with the diluted Lipofectamine in a
volume of 500µl, mixed and incubated for another 20 min. at room temperature. Then
RNA-Lipofectamine complex was added to each well and mixed gently. The complete
growth medium was replaced 6 hours after transfection. Cells were collected for mRNA and
protein analysis 24-

hours post-transfection.

Dual-luciferase Reporter Assay for

-Untranslated Region (UTR) miR-486-5p

Targets
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The whole

- UTR from genes of interest (PDCD4 and Pten) were amplified from

murine genomic DNA and inserted into pGL4 expressing luc2 sequence of firefly luciferase
luc2 vector (Promega, #E6651). Constitutively active cytomegalovirus (CMV) promoter
was used to drive the pGL4 plasmid. Renilla luciferase (Promega, # E2231) was used as
internal control to normalize firefly luciferase activity. Co-transfection of firefly:Renilla coreporter at 50:1 had minimal effect on the firefly luciferase signal (Fig. 2).

Figure 2. Raw relative luminescence units for firefly and co-reporter (Renilla)
luciferase with Dual-luciferase Reporter Assay. Firefly luciferase vector was maintained
at 500 ng, while co-reporter Renilla varied from 500 pg-50 ng. N = 6 for each condition.

H9c2 cells were grown in 96-well plates and transfected with the luciferase constructs
(firefly luciferase:Renilla luciferase construct, 50:1) and a dose curve of miR-486-5p mimics
- UCCUGUACUGAGCUGCCCCGAGGGACGAGGACGAGCACUUCUU-

or siRNA against luc2 gene as positive control (

-UUCCUGCUCCUGCUCGUGAAG-

using

LipofectamineTM 2000. The luciferase activity in the samples was quantified with Dual-

-
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luciferase reporter assay system (Promega, # E1910). After 24 hours of transfection, H9c2
cells were washed with PBS, and lysed by adding 20 µl of 1X passive lysis buffer to each
well and gently shaken at room temperature for 15 min. Firefly fluorescence (F) was
detected by adding 100 µl of Luciferase assay reagent II (Promega, # E1910) to cell lysate;
while Renilla fluorescence (R) was detected by subsequently adding 100 µl of Stop&Glo
reagent (Promega, # E1910). Fluorescence signals were measured with Cytation 5
Multiple-reader (BioTek). Relative luciferase activity = F/R.
Western Blot
105-106 cells were washed twice with 500µl cold PBS and lysed by 100µl cold RIPA
lysis buffer (Sigma, # R0278) supplemented with 10% protease inhibitor, 10% NaVO4 and
10% phosphatase inhibitors PMSF (Sigma, # PPC1010). Lysates were kept on ice for 30
min., and then centrifuged at 10,000xg for 15 min to collect the supernatant for further
analysis. Total protein was measured using BCA Protein Assay Kit (ThermoFisher, #23225).
Cell lysates were diluted 1:5 and standard BSA (ThermoFisher, # 23209) was diluted 1252000µg/ml in RIPA in total volumes of 25µl. Samples were mixed with 200µl BCA working
reagent, incubated at 37oC for 30 min. Absorbance was read at 562 nm by Cytation5 reader
(BioTek). All measurements were triplicated.
For Western blot, 10- 20µg protein was loaded in each well of 10% or 12% sodium
dodecyl sulfate polyacrylamide gel (SDS-PAGE). Electrophoresis was carried out at 75V for
15 min., then 120V for 60 min. Following gel electrophoresis, proteins were blotted onto
0.2 µm pore nitrocellulose membrane at 250 mA for 2 hour at 4oC. After blocking with 5%
non-fat milk in 1X TBS solution at room temperature for 1 hour, the membrane was probed
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with antibodies specific for the protein of interest (Table 5) overnight with constant
agitation at 4oC. Membranes were then incubated with anti-mouse IgG peroxidase
secondary antibody or rabbit IgG for 2 hours at room temperature. Blots were detected
using SuperSignal West Dura Extended Duration Substrate (ThermoFisher, #34075).
Chemiluminescent signal was visualized with the Chemidoc (Biorad). Density of Western
blot bands was quantified with )mageJ and normalized to -actin or GAPDH. For some blots,
membranes were stripped and re-probed to study multiple proteins of interest.
Measurement of LDH Release
The LDH release was measured with the LDH Cytotoxicity Detection Kit (Clontech, #
MK401). Cell-free supernatant from different testing treatments were diluted 10 folds in a
volume of 100 µl, then transferred to a flat-bottom clear 96-well plate. Samples were then
mixed with 100 µl of Reaction Mixture (Clontech, # MK401). After 30 min. of incubation at
37oC while protected from light, 50µl of 1N HCl was added to stop the reaction. Then
absorbance was measured at 490 nm using Cytation 5 reader (BioTek). A standard curve of
LDH (0-90U/ml) LDH (Sigma-Aldrich, #L3888-500UN) and dilution factor were used to
calculate the unit of LDH activity.
TUNEL Staining
Apoptosis post-sim I/R was detected by terminal deoxynucleotidyl transferasemediated dUTP nick-end labeling TUNEL using DeadEnd Fluorometric TUNEL kit

(Promega, # G3250). H9c2 cells were cultured in 8-well chamber slide Nunc Lab-Tek ))

ThermoFisher). After sim I/R, cells were fixed with 4% paraformaldehyde for 25 min. at

4oC. After two rinses with PBS, slides were immersed in permeation solution (0.2% Triton
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X-100 in PBS) for 5 min. Samples were washed twice with PBS, and then were incubated
with TdT reaction mix for 60 min. at 37oC. The cells were counterstained for nuclei using 4',
6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, # H-1200-10). Images were
acquired and analyzed using Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). The

percent of apoptotic cells were calculated the number of TUNEL-positive nuclei to the total
number of DAPI staining nuclei in the same field.
Table 4. List of antibodies used in immunoblotting experiments
Target

Company

Catalogue number

Dilution

PDCD4

Cell Signaling

9535

1:1000

Pten

Cell Signaling

9188

1:1000

total Akt

Cell Signaling

4691

1:1000

phospho Akt (Ser473)

Cell Signaling

4060

1:1000

phospho Akt (Thr308)

Cell Signaling

9275

1:1000

Caspase-3

Cell Signaling

9662

1:1000

cleaved Caspase-3 (Asp175)

Cell Signaling

9664

1:1000

(5A1E)
Bax

Cell Signaling

2772

1:1000

Bcl-2

Cell Signaling

4223

1:1000

HSP-70

Santa Cruz

sc-24

1:1000

Alix (3A9)

Cell Signaling

2171

1:1000

TSG-101 (C2)

Santa Cruz

sc-7964

1:1000

hnRNPA2B1 (B7)

Santa Cruz

sc-374053

1:1000

hnRNPA2B1 (EF67)

Santa Cruz

sc-53531

1:1000
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hnRNPA1 (4B10)

Santa Cruz

sc-32301

1:1000

hnRNPA1 (9H10)

Santa Cruz

sc-56700

1:1000

hnRNPQ (I8E4)

Santa Cruz

sc-56703

1:1000

GAPDH (D16H11)

Cell Signaling

5174

1:1000

Cell Signaling

4970

1:1000

Anti-rabbit

Cell Signaling

7074

1:5000

Anti-mouse

Cell Signaling

7076

1:2000

-actin

Four non-overlapped images of similar total cell numbers were randomly selected from
each coverslip for counting and averaging.
In vivo Administration of miR-486-5p Mimetic
Modified oligonucleotides (miRNA mimetic) have been used to increase microRNA
expression in vivo184; 185. Mimetic of miR-486a-5p (MIMAT0003130,
UCCUGUACUGAGCUGCCCCGAG) was synthesized by Dharmacon (cat. # JLA.061818.A) was
modified to increase resistance against endonucleases as well as cellular uptake,
specifically

-O-methyl modified residues phosphorothioate linkage and

-cholesterol

modifiers, as described in previous study185. B6.129 male and female mice between 10 to

12 weeks old was injected via pericardial sac of either miR-486-5p mimetic or scrambled
non-target miRNA at a dose of 40 µg of oligonucleotides that was complexed in a volume of
l of nanoparticle-based in vivo transfection reagent (Altogen Biosystems, #5030).

Myocardial infarction in vivo was performed 24h after treatment and infarcts assessed as
described above.
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Statistical Analysis
Statistical analyses were conducted with GraphPad Prism 7.0 software. Values were
expressed as mean plus or minus standard deviation (SD). Data was analyzed by using oneway Anova for three or more independent groups or Student s unpaired t-test for two
groups. Statistical significance between groups was set at P

Both a priori and post-

hoc power analysis was used to ensure that sample size is sufficient to achieve statistical
significance. Specific assessment for RNA Seq analyses are described in the appropriate
sections.

CHAPTER III
RESULTS
The overall hypothesis for this dissertation is that RNA-binding proteins are
involved in the selective transport of miRNAs containing specific RNA-sorting sequences
into EVs to exert protective effects against I/R injury. In this section, we describe
experiments to address the hypothesis that RNA-binding proteins mediate the sorting of
specific miRNAs into EVs. To address this this hypothesis, we had to investigate the
repertoire of miRNAs in both producer cells and in their EVs, determine if sets of miRNAs
selectively concentrated in EVs share common sequence motifs, identify the RNA-binding
proteins that interact with these specific miRNAs, and demonstrate functional involvement
of these RNA-binding proteins in active EV sorting events. The results of these experiments
are described and shown below.
Purified MSC-derived EVs Contain RNA
We first sought to isolate EV in conditioned medium from other contaminating
particle populations by differential centrifugation according to the previous study 187 (Fig.
3A). Cellular debris and large vesicles were removed during low and medium speed
centrifugation, whereas EV were concentrated by high-speed centrifugation. Nanosight
nanoparticle tracking analysis (NTA) demonstrated that MSC-derived EVs were 30 to 200
nm diameter vesicles, with a mean diameter of 100 nm (Fig. 3B), while immunoblotting
indicated that EVs expressed the surface markers Alix and TSG101 (Fig. 3D).
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Figure 1. Purification and characterization of wild-type MSC-derived EV. (A)
Schematic of the MSC-derived EV isolation process. (B) Size distribution and concentration
of particles in EVs using nanoparticle analysis (size ~150 nm, concentration~5.8 x 10 10
particles/mL). Plotted data is from one independent experiment (C) Representative
electron microscopic image of EVs. (D) Immunoblotting of EV markers TSG101 (48 kDa),
Alix (96 kDa).
MSC-derived EVs Contain Selectively Packaged miRNAs
Previous studies have indicated the presence of miRNAs in EV fractions 53. To study
miRNAs that are selectively loaded into EVs, we performed an Illumina-based small-RNA
deep sequencing analysis of miRNA profiles in three and four independent biological
replicates of MSC-derived EV and MSC cells respectively. The relative enrichment for each
miRNA was calculated by normalizing to the total number of mapped-miRNA reads. We
found miR-21-5p was the most abundant miRNA in both parent cells and their EV, which is
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in agreement with our previous

study17.

Of these miRNAs in the EV fraction, 155 miRNAs

were found to be upregulated, while 109 miRNAs were down-regulated (p-values adjusted
 0.05) in EV relative to cellular fractions. These results demonstrate that specific miRNAs
are selectively sorted such that higher levels are in EVs relative to producer MSCs (e.g.,
miR-486-5p, miR-122a and miR-451a). For example, miR-486-5p was found at levels
~5853-fold higher in EVs than in MSCs. The next highest differentially expressed EVmiRNA, miR-122a was ~3938-fold higher than in MSC parent cells. In contrast, specific
repertoires of miRNAs were more highly represented in MSCs than in EVs (e.g. miR-1291,
miR-30b-3p, and miR-5121) (Fig. 4). Importantly, the difference between the miRNA
profiles of MSCs and EVs suggests the existence of active processes directing the sorting of
a specific subsets of miRNAs into EVs.
A Subset of EV-enriched miRNAs Harbor a Specific Predicted Sequence Motif
As the sorting of miRNAs into EVs is known to sequence-dependent94; 95, we
performed a bioinformatics comparative analysis using Multiple Em for Motif Elicitation
(MEME) algorithm with Zero-or-one occurrences per sequence (ZOOPS) sequence mixture
model to identify over-represented sequence motifs among miRNAs that are highly
represented in EVs rather than in MSCs as well as miRNAs that are highly retained in the
producer cells188. On the one hand, sequence comparison of top EV-enriched miRNAs
including miR-486-5p, miR-122a, miR-451a, and miR-150a (RPM in EV library >1000, and
p-values adjusted  0.05) revealed that they shared a common short sequence motif
ugGAGUu (Fig. 5A). To date, the specific ugGAGUu sequence we found in subset of miRNAs
in MSC-derived EV has not been implicated in binding with RBPs. On the other hand, we did
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Figure 2. Overview of cellular and vesicular miRNA distribution in MSCs. Small RNAsequencing analysis (Methods) of cellular and vesicular mature miRNAs from MSCs. The
heat map shows expression values, expressed as fold enrichment (FE, red-blue) of mature
miRNAs in cells (CL) versus extracellular vesicles (EVs).
not find this motif in miRNAs that are highly represented in cells relative to EVs such as
miR-1291a, miR-5121a, and miR-16-1-3p. We also identified this group of cell-retained
miRNAs shares a motif of AGAC (Fig. 5B).

Figure 3. Identification of common sequence motifs among top EV-enriched and cellretained miRNAs. Overrepresented motifs in miRNA populations from MSC-derived EVs
(A) (RPM in EV library>1000, and padj  0.05 vs. cells) or MSCs (B) were identified using
the ZOOPs model188.
RNA-binding Proteins are Expressed in MSC-derived EV
In order to investigate the hypothesis that RBPs mediate the sorting of miRNAs into
EVs, we isolated EVs by differential centrifugation (Methods). EVs were characterized
according to the current recommendations of ISEV20. To study which proteins were
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expressed in MSC-derived EVs, we used mass-spectrometry for proteomic analysis
(Methods). We detected 197 different proteins within the EV fraction. Cellular
compartment clustering with DAVID showed that exosomal proteins were enriched in the
EV lysate (Fig. 6A-C). Among the identified proteins, 30 of them were annotated as RNAbinding proteins, according to functional clustering (Fig. 6D). We found several types of
heterogeneous nuclear ribonucleoproteins (hnRNP) expressed in the MSC-derived EVs,
including hnRNPA2B1, hnRNPA1, and hnRNPQ.
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Figure 4. Identification of hnRNPA2B1 as a candidate for EV miRNA sorting protein.
(A) Coomassie stain of MSC EV protein and MSC protein run on SDS-PAGE. (B) Venn
diagram depicts results proteomic analysis of EV and producer cell lysates using mass
spectrometry. A total of 602 MSC and 198 MSC EV proteins were identified by mass
spectrometry with 189 common proteins identified. Gene ontology analysis for cellular
compartment (C) and functional annotations of EV-related proteins (D) using DAVID
Functional Annotation Bioinformatics Analysis176.
Because hnRNPA2B1 is a known RNA binding protein in RNA processing/trafficking,
is known to bind miRNAs, and is secreted by cells into EVs, we focused first on this RBP for
studying the regulation of miRNAs loading into EVs. We confirmed the presence of
hnRNPA2B1 in the EVs by Western blot (Fig. 7A). Furthermore, to identify whether
hnRNPA2B1 is located inside or on the EV surface, purified EVs were treated with
proteinase K with or without pretreatment with 1% Triton X-100 (to break membranes).
The hnRNPA2B1 protein was resistant to proteinase K degradation but was degraded after
treatment with detergent (Fig. 7B). These data showed that hnRNPA2B1 is abundant and
localized primarily in the lumen of EVs.

Figure 5. Identification of hnRNPA2B1 as a candidate for EV miRNA sorting protein.
(A) Immunoblotting for hnRNPA2B1, hnRNPQ, hnRNPA1 and Alix in cells (CL) and
extracellular vesicles (EV) protein lysate. (B) The presence of hnRNPA2B1 in EVs is
validated by immunoblot of hnRNPA2B1 and HSP-70 in MSC-derived EVs isolated from 250
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ml conditioned medium and MSC cellular lysate with or without prior treatment with 1%
Triton X-1000 and degradation with proteinase K (Methods).
Downregulation of hnRNPA2B1 Alters Sorting of miRNA into EVs
In order to study the function of hnRNPA2B1 on miRNA sorting into EVs, we
performed gene editing with CRISPR-Cas9 to knock-down hnRNPA2B1 levels. Because
MSCs have been shown to be resistant to many non-viral transfection methods189, we
employed a lentiviral system. CRISPR guide RNAs (gRNAs) targeting the second exon of the
hnRNPA2B1 open reading frame (ORF) (Methods) were selected using the CRISPR design
tool from Benchling (https://www.benchling.com/crispr/). A non-targeting gRNA
sequence that did not recognize any sequence in the mouse genome was used as negative
control.
We recovered a clone 1.3 A2B1-/- and demonstrated it does not express hnRNPA2B1
by immunoblot analysis (Fig. 8A). The knocking-out of hnRNPA2B1 did not alter
expression of other related RBPs, including hnRNPA1, and hnRNPQ (Fig. 8B). The A2B1-/and Cas9 control cells grew normally under conditions for propagating MSCs.
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Figure 6. Knocking out hnRNPA2B1 with gene-editing CRISPR-Cas9. Representative
example of immunoblotting for hnRNPA2B1 (36 kDa) with two different monoclonal
antibodies against hnRNPA2B1 (SCBT B7 and SCBT EF67) (A), hnRNPA1 (36 kDa) with two
different antibodies against hnRNPA1 (SCBT 4B10 and SCBT 9H10) and hnRNPQ (70 kDa)
(B). Number below the Western blot lane represents ratio of target proteins (hnRNPA2B1,
hnRNPA hnRNPQ -actin.
We determined the effect of knocking out hnRNPA2B1 on miRNA biogenesis or

processing proteins, which could alter the downstream of mature miRNA levels. Western
blot analysis revealed that protein levels of Drosha and Dicer were unchanged after
hnRNPA2B1 was knocked out (Fig. 9). This result supported minimal side effects of
CRISPR-Cas-mediated genome editing.
We found A2B1-/- and Cas9 cell-released particles had a diameter of ~50 to 200 nm
(average ~100nm) with approximately equal number of particles released into the medium
when they reached 100% confluence (5.91 x 1011and 3.39 x 1011 particles/ml for A2B1-/and Cas9) (Fig. 10A) with Nanosight nanoparticle tracking analysis. Immunoblotting
revealed these EVs expressed typical surface markers for EVs including Alix, HSP-70,
TSG

and -actin (Fig. 10B). These data confirmed that knocking out hnRNPA2B1 did

not cause alteration in size distribution or concentration of particles.
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Figure 7. Knock out of hnRNPA2B1 did not alter protein levels of miRNA processing
machinery in MSCs. (A) Immunoblotting results depicted fold change of Drosha and Dicer
in A2B1-/- and Cas9 MSC cell line. (B) Protein band signal intensities were normalized to
GAPDH intensities. Results are represented as mean ± SD (N=3/group) and analyzed using
two-tailed, unpaired t-test. n.s. indicated non-significant, P > 0.05 vs. Cas9 MSC.

Figure 8. Characterization of hnRNPA2B1 knockout (KO) and Cas9 control-derived
EVs. (A) Analysis of WT, CRISPR-Cas9 hnRNPA2B1 KO and CRISPR-Cas9 Control EVs by
nanoparticle tracking analysis showing size distribution and concentration of particles in
EVs (average size ~100 nm, concentration~5.91 x 1011and 3.39 x 1011 particles/ml for
A2B1-/- and Cas9, respectively). Plotted data is from one experiment (N=1) (B)
Immunoblotting of EV markers TSG101 (48 kDa), Alix (96 kDa), HSPkDa -actin
(42 kDa) and hnRNPA2B1 (36 kDa) in extracellular vesicles (EVs) and cells (CLs).
In order to study the role of hnRNPA2B1 in regulation of miRNA sorting to MSCderived EVs, small RNA sequencing and quantitative real time RT-PCR (qRT-PCR) were
performed in cellular and vesicular fraction of A2B1-/- and Cas9 cell line. Our qRT-PCR
analysis demonstrated significant alterations in cellular and vesicular distribution of
several EV-associated miRNAs when hnRNPA2B1 was knocked out. Removal of
hnRNPA2B1 significantly increased the accumulation in the cellular fraction of EV-sorted
miR-122a and miR-486-5p, but did not alter the levels of cell-retained miRNAs including
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miR-1291, miR-5121 (Fig. 11). In contrast, hnRNPA2B1 silencing significantly reduced the
levels of miR-122a and miR-486-5p in EVs (Fig. 12). We did not observe any significant
difference in the vesicular levels of the negative control, miR-22-3p. We also had nonsignificant results with miR-451 (Figs. 11-12).

Figure 9. HnRNPA2B1 mediates the loading of miRNAs into MSC-derived EV. Analysis
of the miRNA levels in cellular fractions after hnRNPA2B1 KO with miScript qRT-PCR (N=6group The values are calculated by the Ct method normalized to small nuclear RNA
(snRNA) U6 levels, and expressed as fold change. All data are presented as the mean ± SD
and analyzed using two-tailed, unpaired t-test, *P  0.05, n.s. non-significant, P > 0.05 vs.
Cas9 CL group.
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Figure 10. HnRNPA2B1 mediates the loading of miRNAs into MSC-derived EV.
Analysis of the miRNA level in vesicular fraction after hnRNPA2B1 knockout with miScript
qRT-PCR (N=6-7/group) via quantification of absolute copy number of miR-122a, miR451a, miR-486-5p, and miR-22-3p. The values are calculated All data are presented as the
mean ± SD and analyzed using two-tailed, unpaired t-test, ***P 0.001, n.s. non-significant,
P > 0.05 vs. Cas9 EV group.
We also employed RNA-sequencing to evaluate differential expression of miRNAs
over a broader dynamic range. Principal-component analysis (PCA) showed a considerable
diversity between miRNA populations of A2B1-/- and Cas9 EV (Fig. 13A). In particular,
detailed RNA-sequence analysis revealed that stable knockout of hnRNPA2B1 caused a
significant reduction in levels of several WT-EV-enriched miRNAs, including miR486-5p,
miR-369 and miR-150a, compared to the Cas9 cells control (Fig. 13B). We also observed a
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trend toward reduction in miR-122a level after hnRNPA2B1 was depleted (p=0.186). These
data confirm that hnRNPA2B1 mediates the loading of a specific group of miRNAs into
MSC-derived EVs. We confirmed by qPCR that this group includes miR-486-5p, miR-122a,
and by RNA-sequencing, may also include miR-369 and miR-150a.

Figure 11. The sorting of miRNAs into MSC-derived EVs is mediated by protein
hnRNPA2B1. (A) Principal-component analysis (PCA) (Methods) for sample-to-sample
distance performed on mature miRNAs identified in KO and Cas9 EVs in three independent
biological replicates. (B) Heat map showing expression values, expressed as fold
enrichment (FE; blue-red) of mature miRNAs in hnRNPA2B1 knockout EV (KO) versus
Cas9 control cells (Cas9).
Interaction of hnRNPA2B1 and EV-enriched miRNAs
Because hnRNPA2B1 is a well-known RNA-binding protein, we selected miRNAs
shown to be EV-sorted, miR-486-5p, miR-122a (Fig. 2, 3, 12) and miR-451a which was
shown in initial assays to be sorted (Figs. 2,3), but not validated by PCR (Fig. 12) for
studies of interaction (i.e. binding) with hnRNPA2B1. The binding of hnRNPA2B1 to miR486-5p, miR-451a, and miR-122a were first tested by electrophoretic mobility gel-shift
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assay. The protein-miRNA complex was detected based on their mobility shift relative to
controls. The specificity of the interaction was evaluated by competition and super-shift
assays. In the competition assay, reduction in the shifted band was observed when excess
amount (50-fold) of unlabeled miR-122a, miR-486-5p and miR-451a was added to the
binding reaction, indicating the unlabeled miRNA can compete with labeled miRNA for
binding to RBPs (Fig. 14). The protein specificity of interaction was determined by gel
super-shift assay (Methods). The addition of the monoclonal antibody against hnRNPA2B1
to the mixture of nuclear lysate and biotinylated miRs causes a super-shift, resulting in a
reduction in intensity of the initially shifted bands (RNA and protein) and accumulation of
complexes in the well (RNA-protein-antibody). Moreover, the nuclear lysate of A2B1 -/- did
not cause a shift in the presence or absence of antibody for hnRNPA2B1 (Fig. 15). Although
we tried to get the super shift complexes into the gel by changing the acrylamide gel
percentage or charge of the protein-RNA complex, we could not resolve the complex in the
gel, which made it difficult to make even a semi-quantitative analysis.
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Figure 12. Specificity of in vitro interaction between EV-enriched miRNA and RNAbinding proteins in WT-MSC nuclear lysate. Biotinylated miRNAs were incubated with
nuclear lysates from WT-MSC in the absence or presence of 50-fold excess of unlabeled
cognate miRNA. Electrophoretic shift showed the binding of hnRNPA2B1 to miR-122a,
miR-486-5p, and miR-451a. The specificity of protein-RNA interaction was determined by
the competition assay with unlabeled miRNA.

Figure 13. HnRNPA2B1 interacts with EV-enriched miRNAs in vitro. Electrophoresis
mobility super-shift assay (EMSA) shows the binding of proteins to miR-122a, miR-486-5p,
and miR-451a. Biotinylated miRNAs were incubated with either nuclear lysate from WT or
hnRNPA2B1 knockout nuclear lysate with or without antibody against hnRNPA2B1 as
indicated.
The specific binding of hnRNPA2B1 to EV-associated miRNAs was verified by RNA
immunoprecipitation (RIP) assay of hnRNPA2B1 using magnetic beads and nuclear lysates
as input, followed by qRT-PCR for mature miRNAs. We detected the presence of
hnRNPA2B1 protein in the sample immunoprecipitated with antibody against hnRNPA2B1,
but not in the anti-IgG control antibody (Fig. 16A). The miR-486-5p was significantly
enriched in hnRNPA2B1 precipitates (P  0.05) (Fig. 16B). In contrast, no significant
difference was observed in enrichment of cell-retained miR-1291 and miR-5121 (Fig. 16B).
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We also could not detect significant enrichment for miR-451a and miR-122a, though trends
in that direction were noted.

Figure 14. Association of hnRNPA2B1 and EV-enriched miRNAs by RIP assay. (A).
Immunoblots for hnRNPA2B1 (36 kDa) in elutants and supernatants following RNA
immunoprecipitation assay. (B) qPCR analysis of miRNAs contained in hnRNPA2B1
immunoprecipitates from WT-MSC nuclear lysates as a percentage of 10% input.
Immunoprecipitation was performed with mouse anti-hnRNPA2B1 or anti-IgG control
antibody (N=6/group) (Methods). All data are presented as the mean ± SD, and analyzed
using two-tailed, unpaired t-test, *P  0.05, n.s. non-significant, P > 0.05 vs. IgG control
group.
To validate the observations from the RIP assay, the predicted binding of
hnRNPA2B1 and miR-122a, miR-451a and miR-486-5 were confirmed with the
biotinylated miRNA-mediated pull-down assay (RNA/protein pull-down assay). The
hnRNPA2B1 protein was detected in samples precipitated with labeled miR-122a, miR451a and miR-486-5p but not with labeled miR-1291 (Fig. 17A). To confirm the specificity
of interaction between miR-486-5p and hnRNPA2B1, we performed a competition assay
with excess unlabeled miR-486-5p. Binding of hnRNPA2B1 and miR-486 was reduced
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when an excess amount (20X) of unlabeled miR-486-5p was added to the reactions (Fig.
17B). These data strongly support the association of hnRNPA2B1 and miR-486-5p, the
most enriched miRNA in MSC-derived EVs.

Figure 15. Pulldown of hnRNPA2B1with biotinylated miRNAs. For RNA/protein pulldown assay (A) and for competition assay (B), nuclear extracts were mixed with
biotinylated miR-122a, miR-451a, miR-486-5p, miR-1291a or nonbiotinylated miR-486-5p,
respectively.
Summary of the Findings
The mRNA content of extracellular vesicles is important for intercellular
communication. Deep sequencing data for small non-coding RNA from our lab
demonstrates that specific miRNAs are selectively loaded such that relative levels differ
between EVs and producer MSCs. Several miRNAs (including miR-486-5p, miR-122a) had
high abundance in EVs and yet low levels in the producer cells. The difference between the
miRNA profiles of cells and EVs suggests the existence of active processes directing the
sorting of miRNAs into EVs. We hypothesized that RNA-binding proteins are key
components of the miRNA selective sorting apparatus. From mass-spec and bioinformatic
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analyses, we selected the hnRNPA2B1 protein as a good candidate for mediating the
sorting of EV-enriched miRNAs. To this aim, we knocked-out transcripts encoding
hnRNPA2B1 using CRISPR-Cas9. The expression of hnRNPA2B1 was completely knocked
out, as far as we could tell from Western blot validation. Knocking out of hnRNPA2B1 does
not affect other RNPs that might be involved in miRNA sorting, including hnRNPA1,
hnRNPQ and YBX1. Deletion of hnRNPA2B1 also does not alter EV production, size, or
expression of EV markers (TSG101, HSP70, CD63). Analysis of miRNA levels by qRT-PCR
showed that levels of miR-122a and miR-486-5p were significantly reduced in the EV
fractions, and that their cellular levels were increased, supporting dysfunction of EV sorting
of these miRNAs. Levels of cell-retained miRNAs (miR-1291a and miR-5121a) did not
change in either knock-out or control cells. We showed that hnRNPA2B1 binds to miR-4865p, which was confirmed by independent assays, including, RNA immunoprecipitation and
the miRNA-mediated pulldown assays (Fig. 18). The status of miR-451a and miR-122a
were ambiguous due to the fact that results were not uniformly supportive of sorting and
hnRNPA2B1 interaction.
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Figure 16. Graphical summary of the study findings in the Aim 1. The
hnRNPA2B1protein binds to a specific group of miRNAs, including miR-486-5p.
Downregulation of hnRNPA2B1 causes a decrease in EV levels of miR-486-5p, thus leading
to an accumulation of the miRNA in the intracellular compartment. This supports our
hypothesis of a role for hnRNPA2B1 in EV sorting of miR-486-5p.
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Cardioprotective effects of EV selectively sorted miR-486-5p
Extracellular vesicles are known to package and transfer miRNA from producer cells
to recipient cells to modulate gene/protein expression and contribute to the survival
and/or reparative processes during and after I/R injury. In the current study, we found
high levels of miR-486-5p within the MSC-derived EV, evidenced by deep RNA-sequencing
(Fig. 4) and qRT-PCR (Fig. 19). This finding is consistent with other studies that show miR486-5p was among top over-expressed miRNAs in EVs isolated from human adipose and
bone-marrow MSCs190. Additionally, we reported previously that the protective effects of
MSC-derived EVs was mediated largely by miR-21-5p. Removal of miR-21-5p did not
however, completely abolish the protection, indicating other miRNAs also contributed to
this beneficial effect. We identified miR-486-5p as a candidate in mediating cell survival
effects. In Aim 2, we used different assays to address the hypothesis that miR-486-5p, a
selectively sorted EV miRNA, can reduce cell death-associated with I/R injury, resulting in
less cellular damage and smaller infarct size. To examine the protective effect of this EVenriched miRNA against MI-mediated damage, we verified function using in vitro and in
vivo models, identified targets of miR-486-5p, and determined the biological significance of
miR-486-5p after I/R injury.
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Figure 17. Validation of miR-486-5p expression in MSC cells (MSC CL) and
extracellular vesicle (MSC EV) samples. miScript small RNA qRT-PCR results expressed
as number of miR-486a-5p copies using a standard curve of miR-486-5p mimetic. Data is
represented as mean ± SD (N=7/group) and analyzed using a two-tailed, unpaired t-test. **
P
vs MSC CL
Prediction and Selection of Targets for miR-486-5p Involved in Regulation of Cell
Death in MI
miRNAs have been shown to regulate multiple mRNA targets to exert their
biological functions. Because the consistency and accuracy of commonly used algorithms in
miRNA target prediction are typically low191, we decided to combine two algorithms
(MiRanda192 and Targetscan 7.169) for predicting miRNA-mRNA target interactions,
resulting in 1687 miRNA-target pairs. From theses putative targets, our gene ontology
analysis (StudioPathway193) (targets contributing to cell survival or cell death) resulted in a
final set of 64 miRNA-target pairs. Based on cumulative interaction context scores 69,
Programed cell death 4 (PDCD4) and Pten, a well-known target of miR-486-5p194; 195 were
chosen to study further (Fig. 20).
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Figure 18. Scheme for selecting and prioritizing miR-486-5p and potential targets
linked to cell survival. Starting with EV-enriched miR-486-5p and its associated targets
defined by MiRanda and TargetScan (version 7.1) databases, we narrowed down our
analysis to candidates with annotation pertaining to apoptosis cell death and
survival pathways from PathwayStudio
miR-486- p Targets PDCD through Binding with the

UTR and Inhibits Protein

Levels
The profound effect of miRNAs on protein levels is usually through binding of its
seed sequence to complementary regions of the mRNA targets most often in the
translated region

un-

-UTR). Bioinformatic search indicated target sequences for miR-486-

5p at nucleotide (nt) 63-69 and nt 721-

of the -UTRs of PDCD4 and Pten respectively.

We also found that the miR-486-5p target sequences of PDCD4 and Pten- -UTRs are highly
conserved among seven species, including humans (Fig. 21). Such sequence conservation
may be indicative of conserved function. We next used a reporter luciferase assay to test
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whether miR-486- p directly targeted the

-UTRs of PDCD and Pten We cloned the

-

UTRs of PDCD4 and Pten into a luc2-SV40 reporter vector. This vector puts the luc gene

under control of the cloned

UTR and repression of the reporter luc signal is due to

repressed translation of luc196. We observed a profound reduction of luciferase activity by
miR-486-5p mimic compared to the scrambled miRNA controls (P  0.0001) (Fig. 22)
when H9c2 cells were co-transfected with the reporter vector and different doses of miR486-5p mimetic or siRNA against luc2 gene as positive control. We also observed similar
result with the construct of

-UTR of Pten (Fig. 22 indicating both

-UTRs of PDCD4 and

Pten are definite targets for miR-486-5p binding and suppression of post-transcriptional
regulation.

Figure 19. Binding Site of miR-486- p on the -UTR of PDCD4 and Pten is Highly
Conserved in Seven Species. Comparison of nucleotides between the seed sequence of
miR-486-5p and its targets in seven species. Data were retrieved from targetscan.org,
release 7.1.
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Figure 20. miR-486- p Targets the -UTRs of PDCD4 and Pten. 1 x 104 H9c2 cells were
co-transfected with PDCD4 or Pten firefly luciferase reporter plasmids, Renilla luciferase
plasmid (50:1) and amounts to comprise a dose curve of miR-486-5p mimic. Scrambled
non-targeting miRNA was used as negative control (scramble) and siRNA against the luc2
gene (100nM) was used as positive control. After 24h, cells were lysed and both firefly and
Renilla luciferase activities were measured. Data are presented as the relative ratio of
firefly:Renilla luciferase, normalized to scramble treated group, with error bars
representing SD (N=4/group) and analyzed using one-way ANOVA. ****P  0.0001 vs.
scramble group.
We next asked if the potential of miR-486-5p to regulate PDCD4 and Pten was
functional for the endogenous genes products. H9c2 cells were transfected with miR-4865p mimic, and scrambled miRNA and the effect of these manipulations upon mRNA and
protein levels of PDCD Pten and phosphorylated Akt Pten s downstream targets were
measured by qRT-PCR and Western blotting. We found the transfection of miR-486-5p

mimetic significantly increased levels of mature miR-486-5p (Fig. 23A). We observed that
mRNA levels of PDCD4 and Pten were significantly reduced in the group transfected with
miR-486-5p mimetic, compared to the scramble control group (P  0.05) (Fig. 23B).
Subsequently, PDCD4 protein levels were reduced by approximately 50% (Fig. 23C-D). On
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the other hand, the miR-486-5p mimic did not affect protein levels of Pten or
phosphorylated Akt (Fig. 23C-D). These findings demonstrated that miR-486-5p inhibits
PDCD4 via targeting the PDCD4 mRNA and limiting the production of PDCD4 protein.

Figure 21. miR-486-5p Mimic Decrease mRNA and Protein Levels of PDCD4. 1 x 104
H9c2 cells were transfected with 50 nM of synthetic miR-486-5p mimic for 24 hours (for
RNA isolation) or 48 hours (for protein isolation). Scrambled non-targeting miRNA was
used as negative control (A) mature miR-486-5p levels in transfected cells 24 hours posttransfection detected by qRT-PCR The values are calculated by the Ct method and
normalized to U6 (B, C, D) Expression of miR-486-5p targets (PDCD4 and Pten) RNA (B)
and protein levels (PDCD4, Pten, phosphorylated Akt (pAkt), total Akt (tAkt) (C, D) 24
hours after miR-486-5p transfection. The qRT-PCR data are calculated by the Ct method
and normalized to 18S. Protein bands signal intensities were normalized to GAPDH. Results
are presented as the average fold change ± SD (N=3/group) and analyzed using two-tailed,
unpaired t-test. *P  0.05; **P  0.01, ****P  0.0001 vs. scramble group
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miR-486-5p Mimetic Increases Cell Survival after Simulated I/R Injury
In order to study the effect of miR-486-5p mimetic treatment on I/R injury, we next
performed the simulated ischemia reperfusion injury (sim I/R). We transfected H9c2 cells
with either miR-486-5p mimetic, or non-targeting scrambled RNA. 48h after transfection,
cells were challenged with sim I/R by hypoxia for 12 hours in ischemia mimetic solution,
followed by 2 hours reperfusion in normal growth medium (Methods). The number of I/Rinduced necrotic cells was evaluated by Hoechst 33258 propidium iodide staining. We
found that pretreatment with miR-486-5p mimetic did not change the cell viability in
normal conditions (Fig. 24). However, a significant increase in cell survival was observed
for the miR-486-5p mimetic treated group (Fig. 26A-B) after sim I/R (P  0.05).
Representative images of Hoechst/PPI double-staining of H9c2 cells treated with
scrambled non-targeting control, or miR-486-5p mimic are shown in Fig. 26A.
Additionally, released lactate dehydrogenase (LDH) into cell culture medium was used as
additional indicator for damaged plasma membrane. In accordance with results in cell
viability measurement with Hoechst/PPI staining, transfection of miR-486-5p mimetic at
50 and 100nM significantly reduced LDH release, relative to scrambled group (P  0.05)
(Fig. 25). These data suggested that miR-486-5p pretreatment promotes cell survival of
H9c2 cells after sim I/R.
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Figure 22. The miR-486-5p does not Affect Cell Survival in Normoxic Conditions. 1 x
104 H9c2 cells were transfected with a dose curve of miR-486-5p mimic for 48 hours.
Scrambled non-targeting miRNA was used as negative control (scramble). Percentage (%)
of cell viability was measured by number of viable cells using Hoechst and PPI staining
before and after 16 hours in normoxia condition. Data are represented as mean ± SD
(N=4/group) and analyzed using one-way ANOVA. n.s., non-significant, P > 0.05 vs.
scramble group.

Figure 23. Measure LDH Release after sim I/R. (A). Standard curve of LDH. (B)
Quantification of LDH release (mU/mL) by H9c2 cells into the medium after sim I/R using a
standard curve of LDH. Results are represented as mean ± SD. (N=4/group) and analyzed
using one-way ANOVA. *P  0.05 vs. scramble group. LDH, Lactate dehydrogenase, sim I/R,
simulated Ischemia/reperfusion.
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Figure 24. miR-486-5p Mimic Increases Cell Survival after sim I/R. 1 x 104 H9c2 cells
were transfected with a dose curve of miR-486-5p mimic for 48 hour before subjected to
12 hours ischemia and 2 hours reperfusion (Methods). Scrambled non-targeting miRNA
was used as negative control (scramble). (A) Representative images demonstrate PPIpositive nuclei (red color) of dead cells, all nuclei, Hoechst-positive (blue color) after sim
I/R (×4 magnification). Scale bar = 1000 µm (B). Quantification of cell viability, the
percentage (%) of cell survival was measured by number of viable cells using Hoechst and
PPI staining before and after sim I/R (C) Quantification of LDH release (mU/mL) by H9c2
cells into the medium after sim I/R using a standard curve of LDH. Results are represented
as mean ± SD. (N=4/group) and analyzed using one-way ANOVA. *P  0.05 vs. scramble
group. LDH, Lactate dehydrogenase, sim I/R, simulated Ischemia/reperfusion.
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miR-486-5p Down Regulates PDCD4 Levels and Inhibits I/R Injury-induced
Apoptosis In vitro
Since EV-derived miR-486-5p targets PDCD4195, a mediator of apoptosis, and
increases cell viability after sim I/R (Fig. 25-26), we hypothesized that miR-486-5p
functions by inhibiting cell apoptosis of H9c2 cardiomyocyte. DNA fragmentation as a
characteristic hallmark of apoptosis was identified and quantified using TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end labeling) staining. TUNEL assay after sim I/R
revealed that sim I/R challenge significantly increased the number of apoptotic cells ~40%
compared with control cells in the normoxic condition. In accordance with the data
observed in the simulated I/R, pretreatment with miR-486-5p significantly inhibited sim
I/R-induced apoptosis (P  0.05) (Fig. 27 A-B). In addition, PDCD4 has been reported to
induce apoptosis via activation of caspase-3 and Bax196,197. We found miR-486-5p
treatment effectively reduces the protein levels of the pro-apoptotic proteins PDCD4,
cleaved caspase-3/total caspase-3 and Bax, after sim I/R (Fig. 28 A-B). Therefore, we
concluded that miR-486-5p increases cell survival in H9c2 cells by inhibiting apoptosis via
PDCD4 repression.
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Figure 25. miR-486-5p Reduces Apoptotic Cell Death after sim I/R. 1 x 104 H9c2 cells
were transfected with 50 nM miR-486-5p mimic for 48 hours. Scrambled non-targeting
miRNA was used as negative control (scramble). They were then subjected to sim I/R
challenge (Methods). After sim I/R, cells were fixed for TUNEL assay. (A) Representative
images demonstrate TUNEL-positive nuclei (green color) (×20 magnification). Scale bar =
100 µm. (B) quantification of percentages (%) of TUNEL-positive cells relative to DAPIpositive total nuclei. Results are represented as mean ± SD (N=4/group) and analyzed
using one-way ANOVA. *P  0.05, ***P  0.001 vs. scrambled group. TUNEL, Terminal
deoxynucleotidyl transferase dUTP nick end labeling, Sim I/R, simulated
ischemia/reperfusion.
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Figure 26. miR-486-5p Reduces Pro-apoptotic Protein Levels after sim I/R. 1 x 104
H9c2 cells were transfected with 50 nM miR-486-5p mimetic or non-targeting miRNA for
48 hours. Scrambled non-targeting miRNA was used as negative control (scramble). They
were then subjected to sim I/R challenge. After sim I/R, cells were lysed for Western blot
using RIPA buffer (Methods). (A) Levels of PDCD4, Pten, cleaved caspase-3, Bcl-2 and Bax
via Western blot analysis B Protein levels were normalized to that of -actin. Results are
represented as mean ± SD (N=3/group) and are analyzed using a two-tailed, unpaired ttest. n.s., non-significant *P  0.05, **P  0.01, ***P  0.001 vs. scramble group. Sim I/R,
simulated ischemia/reperfusion
miR-486-5p Mimetic Reduces Infarct Size In vivo
The potential effect of EV-enriched miR-486-5p in protection against I/R injury in
vivo was examined in B6/129 mice. Mice were treated with miR-486-5p mimetic or
scramble non-targeting miRNA control by pericardial sac injection of a mimic/lipid
complex (Methods) and subjected to I/R injury (Methods) (Fig. 29A). There was a
significant 28% reduction (P  0.05) in infarct size as percentage of the area at risk in
group treated with miR-486-5p mimic, compared to non-targeting scramble control (Fig.
29B-C). Taken together, both the in vitro and the in vivo data support the hypothesis that
miR-486-5p is protective against ischemia reperfusion-induced injury.
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Figure 27. miR-486-5p Reduces Infarct Size in an in vivo Model of MI. (A) Timeline for
in vivo experiment: 24 hours prior to I/R injury, mice were injected with either miR-486-5p
mimic/lipid complex (Methods) or scrambled complex into the pericardial sac and were
recovered overnight. Scrambled non-targeting miRNA was used as negative control
(scramble). 24 hours after I/R injury, hearts were collected and stained with TTC, and
sectioned for infarct size, and risk region measurements. (B) Representative images of
phthalo blue dye and TTC-stained heart slices from the mice pre-treated with scrambled or
miR-486-5p mimic after 45 min. ischemia and 24 hours reperfusion. Blue color is the area
not at risk; red color is TTC staining indicating the areas at risk (red plus white); white
color is the infarcted area. (C) Infarct sizes were measured as the average infarcted percent
of the risk region (white/red), error bars represent SD (N=7/group). *P=0.0175 vs.
scrambled group (two-tailed, unpaired t-test). MI, myocardial infarction, I/R,
ischemia/reperfusion, TTC, triphenyltetrazolium chloride.
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Summary of the Findings

We have reported that MSC-derived exosomes protect cardiomyocytes from
ischemia-reperfusion (I/R) induced myocardial injury both in vitro and in vivo17. We found
that miRNA-486-5p (miR-486-5p) was highly and selectively expressed in MSC-derived
exosomes. The role of miR-486-5p in cell survival is still debated and miR-486-5p has been
reported to act as either a tumor suppressor or an oncogene 192,198,199. We hypothesized that
increased levels of miR-486-5p will protect cardiomyocytes from I/R injury. Simulated
ischemia/reperfusion was performed on H9c2 cells treated with miR-486 mimic or
scrambled control to measure the cytoprotective effect of miR-486-5p. H9c2 cells treated
with the mimic of miR-486-5p showed a significant increase in cell survival by 35% and a
reduction of 20% in LDH release compared to control cells treated with non-targeting
scrambled miRNA.
We searched for miR-486-5p gene targets using miRanda and Targetscan and
focused upon targets involving in the cell death and survival pathways. Program cell death
4 (PDCD4), a tumor suppressor and PTEN, which negatively regulates the PI3K/Akt
survival pathway, were chosen for further study based upon considerations of scores for
mRNA-miRNA interaction and the predicted targets. Luciferase reporter gene assays
indicated that the

-UTRs of PDCD4 and PTEN are targeted by miR-486-5p.

Immunoblotting results showed a 50% reduction in PDCD4 protein levels with the miR486-5p mimic. Western blot results with cell lysates after sim I/R showed marked
decreased levels of PDCD4, cleaved-Caspase 3 and Bax level in the group treated with miR486-5p mimic compared to control cells. Pericardial sac injection of miR-486-5p mimic
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before animals were subjected to ischemia (45 min) followed by overnight reperfusion
significantly reduced infarct size by 28% (P  0.05) compared to the scrambled treated
group. These findings support that miR-486-5p upregulation is cardioprotective by
targeting PDCD4 thereby reducing apoptosis.

CHAPTER IV
DISCUSSION
Cardiovascular diseases remain the leading cause of death in the USA and globally 1.
Several types of stem cells, including mesenchymal stem cells (MSC) have been studied for
potential to repair injured myocardial tissue and improve cardiac function in MI 109. Even
though stem cells had low retention rate post-transplantation, small beneficial effects were
observed, though these were unrelated to transdifferentiation and replacement of dead
cells by stem cell derivatives115; 116; 118; 202. This observation inspired the paracrine
hypothesis that MSCs mediate reparative effects through secreted factors including EVs 18;
202.

EVs derived from MSCs can recapitulate cardioprotective potential of their source cells

with a less immunogenic capacity. Delivery of MSC-derived EVs protects against cardiac
ischemia/reperfusion injury18; 171, and the role of small non-coding miRNA in EVs cargoes
has been implicated in the salvage process 17; 84; 203. Previously, we demonstrated the
cardioprotective effects of MSC-EVs in preconditioning against I/R injury by miR-21-5p17.
However, depletion of miR-21-5p from MSC-EVs did not completely abrogate their
cardioprotective effects, suggesting the potential involvement of other cardioprotective
miRNAs in the EV cargo.
In this present study, we described the mechanism that regulates the sorting of
miRNAs into MSC-derived EVs and studied the functional roles of secreted miRNA in the
context of I/R injury. Our results indicated miR-486-5p is a particularly enriched nucleic
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acid cargo that is selectively packaged into MSC EVs in comparison to producer MSCs. In
this dissertation we sought to investigate whether RNA-binding proteins in the nuclear
lysate of MSCs could interact with EVs-enriched miRNAs. We identified that hnRNPA2B1 is
required for the efficient loading of miR-486-5p into MSC-derived EVs. Our findings also
showed that miR-486-5p in turn has a significant positive impact on viability of
cardiomyocytes after MI via inhibition of PDCD4 and apoptosis post-I/R injury.
RNA Binding Protein-mediated Loading of miRNAs into EVs
Consideration of miRNA as EV cargo is increasingly of interest. The packaging of
these miRNAs into extracellular vesicles is still incompletely understood. Overexpression
of miRNAs enriches its expression level in EVs. In some instances, this may occur by mass
action and is not selective. This is how we envision miR-21-5p is loaded into EVs as it
appears not to be selectively increased in EVs relative to producer cells, and knockout
MSCs and EVs both lack the miR-21-5p17. There have been multiple studies that have
uncovered several pathways for selective loading of specific miRs into EVs and these are
cell-type and situation specific78; 79; 94; 95; 96. Specific miRNA regions have been proposed to
contain short localization signals that facilitate miRNA cargo loading53. Alternatively, cargo
active selection may occur via an AGO2 protein association with the RISC complex for
specific miRNAs77. The YBX178 and La RNA binding proteins79 have been reported to direct
specific miRNA loading into EVs, and post transcriptional modification of certain miRNAs in
the form of a -end uridylation also facilitates miRNA loading 96. Analysis of RNA Seq data

from MSC and MSC-derived EVs demonstrated a series of eight miRs that were increased in
EVs vs. parental MSC, and use of MEME software188 suggested a specific sequence motif that
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was present in this set of miRs (Fig. 5). This motif, ugAGuu, had a perfect conservation of
the core AG element, and was not present in miRNAs that were not selectively sorted to
EVs (Fig. 5A). Importantly, this potential miRNA motif was not in miRNAs that were not
selectively sorted to MSC-derived EVs has not been previously described (Fig. 5B). Thus,
based on background information and our data, we hypothesized that a specific RNA
binding protein or proteins may be involved in the selective sorting of this set of miRs into
MSC EVs. Besides miR-486-5p, we also found miR-122a and miR-451a were highly
enriched in MSC-EVs (Fig. 4) and decided to choose them to study further the active sorting
mechanism, because of their levels in MSC-derived EVs.
In order to identify potential RNA binding proteins for this motif, we performed
mass spectrometry and western blot analyses and discovered the presence of several
potential RNA binding proteins which have been shown to mediate the sorting/trafficking
of miRNAs including hnRNPA2B1, hnRNPA1, and hnRNPQ (Fig. 7). We hypothesized that
these RBP could be involved in the packaging of miRNAs into EVs. The goals of Aim 1 were
to better understand the role of RNA-binding proteins in mediating EVs-enriched miRNAs,
and determine the association of RNA-binding protein with specific EVs miRNAs.
Identifying mechanisms for sorting miRNA into EVs will contribute to better understanding
of miRNA loading events, and help to develop new strategies to engineer the miRNAs cargo
of MSC-EVs.
We focused our investigation on hnRNPA2B1 to study the regulation of miRNAs
packaging into MSC-EV due to its abundance in EVs among other RNA-binding proteins and
its predicted strong binding of AG core sequences (Figs. 6-7). The hnRNPA2B1 protein is a
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multi-functional RNA binding protein that participates in RNA processing and
trafficking204. In the nucleus, hnRNPA2B1 is a component of core particles that bind to premiRNAs in the nucleus, while it facilitates the transport of some localized mRNAs in the
cytoplasm204. Through its interaction with a 21-nucleotide RNA trafficking sequence,
hnRNPA2B1 has been reported to be involved in cytoplasmic RNA transport to axons in
neural cells205; 206. A recent study showed that hnRNPA2B1 binds to mRNA carried N6methyladenosine (m6A) modification and mediates the processing of nuclear
transcripts207. Crystallographic analysis revealed that hnRNPA2B1 has two RNA
recognition motifs (RRM) -1, -2. Both RRMs specifically recognize AG core motifs 204.
Interestingly, Villarroya-Beltri et al. reported that hnRNPA2B1 interacts with miRNA
harboring the EXO-motif GGAU (e.g., miR-198, and miR-601) and controls their loading into
EV secreted by lymphocytes94. In a recent study, hnRNPA2B1 was identified to be
necessary for the sorting of miR-17/93 into microvesicles of lung epithelial cells 208. The
AGG and UAG motifs that are necessary for the interaction of RNA molecules with the
RRM1 and RRM2 domains, were present in the hnRNPA2B1-associated miRNAs (miR-17, 20a, and -93)208. In addition, other studies suggested the role of hnRNPA2B1 in controlling
the packaging of lncRNAs into EVs. In one study, the accumulation of lncRNA H19 within
EVs was dependent on hnRNPA2B1, leading to resistance to tyrosine kinase inhibitor,
gefitinib in non-small cell lung cancer (NSCLC)209. Overexpression of hnRNPA2B1 increased
expression of exosomal lncRNA H19, whereas the opposite result was reported when
hnRNPA2B1 was knocked down. The binding of lncRNA H19 to hnRNPA2B1 was reduced
when the specific motif GGAG located at the

-end of this lncRNA was mutated 209. Another

96
study supported the role of hnRNPA2B1 for sorting lncRNA LNMAT2 into EVs derived from
bladder cancer cells, thus promoting lymphatic metastasis210. The author also reported the
presence of the specific motif GGAG on the hnRNPA2B1 binding sites of lncRNA
LNMAT2210. Additionally, hnRNPA2B1 was also annotated as cargo of EVs from many cell
types in the exosome database Exocarta 211.
A loss-of-function approach with CRISPR-Cas9 genome editing was used to evaluate
the function of hnRNPA2B1via a loss-of-function approach. We chose to target the second
exon of the hnRNPA2B1since this exon is present in all splice variants, and thus would
cause loss-of-function by premature stop codon. The gene ablated MSCs and their EV
derivatives showed no expression of hnRNPA2B1 by Western blot while expression of
other RBPs including hnRNPA1, hnRNPQ and proteins involved in miRNA biogenesis
including Drosha and Dicer were not altered (Fig. 8). In addition, EV markers, and EV size
and distribution were unaffected (Fig. 9). We next sought to evaluate the effects of
hnRNPA2B1 ablation upon miRNA sorting into EVs.
First, we performed RNA Seq once again, this time comparing the profiles of EVs
from Cas9 control and hnRNPA2B1 KO EVs. We observed that expression levels of vesicular
miRNAs including miR-486-5p and other miRNAs identified as selectively sorted by the
initial RNASeq data (miR-369-3p, miR-150-5p, miR-486b-5p, miR-486a-5p) (Figs. 12 vs. 4)
were suppressed in EVs by the removal of hnRNPA2B1. There was also a non-significant
trend towards a reduction in expression levels of miR-122a-5p, which was initially found to
be increased in EVs (Fig. 4). We noted, for example, that silencing of hnRNPA2B1
prevented the transfer of miR-486-5p, one of the more highly expressed miRNAs in the
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original EVs, from cell to EV, resulting in an accumulation of miR-486-5p in the cellular
compartment of hnRNPA2B1 knock-out cells. We performed real-time RT-PCR on selected
miRNAs to confirm the results of the Cas9 PA2B1 KO analysis (Figs. 10 and 11), and these
results confirmed the hnRNPA2B1 dependency of EV loading for miR-122a, and miR-486a5p (Fig. 11).
We next sought verification for binding of hnRNPA2B1 with specific miRNAs using a
variety of biochemical assays. The predicted binding of miR-486-5p to hnRNPA2B1 was
confirmed via electrophoretic gel-shift assay, RNA immunoprecipitation and UV crosslinked biotinylated RNA pull-down assay (Figs. 13-17). Additionally, we also identified a
common sequence motif shared by EV-enriched miRNAs, ugAGuu motif, with the MEME
Suite program. This new motif has the same AG core motif which exists in the EXOmotif
GGAG94; 204. Although we have evaluated the effect of complete silencing of hnRNPA2B1
upon miRNA sorting into MSC-derived EV, we were unable to test the effects of
overexpression of hnRNPA2B1 or the role of ugAGuu motif with mutational approaches
(see Limitations and Future Directions). Of note, miR-122a-5p also exhibits GGAG motif
which has been previously described sorting motif for hnRNPA2B1 in T-cells94. This GGAG
motif was overlapped with the ugAGuu motif we found in some of the MSC-EV enriched
miRNAs, notably, miR-122-5p (Fig. 5). We did not observed a clear statistically significant
relationship between miR-122a-5p and hnRNPA2B1 in the context of MSC cells, indicating
miRNA sorting may be cell type specific. It is also possible that other proteins bind
overlapping sites, reducing the hnRNPA2B1 binding in the case of miR-122-5p. A future
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study will focus on the biological effects of increased/decreased miR-486-5p export into
EVs in overexpression or knockout hnRNPA2B1 experiments.
Given the essential role of RBPs in RNA trafficking and metabolism as well as recent
reports on the mechanism of RNA loading into EVs 94; 95, understanding the RBPs involved
in EV packaging of specific miRNAs would provide our first insights into the mechanism of
this phenomenon. Our data demonstrated the key role of hnRNPA2B1 in mediating miRNA
sorting of a limited set of specific MSC miRNAs into EVs. Further, EV cargo miRNAs are
emerging as diagnostic and prognostic biomarkers for cardiovascular diseases. New
insights into the regulation of miRNA sorting can help to understand circulating miRNA
biomarkers and contribute to development of new therapies based on the transfer of EVassociated miRNAs.
Physiological Role of EV-enriched MicroRNAs
As part of a paracrine mechanism, vesicles secreted from bone marrow derived
stem cells have been shown to decrease infarct size and slow progression of heart failure in
models of cardiac ischemia/reperfusion injury. MSC-derived EVs have demonstrated the
ability to ameliorate tissue injury via their miRNA and protein cargoes 18; 171; 172. A recent
study from our laboratory showed that miR-21-5p is a key factor behind the protective
effect of MSC derived EVs against MI 17. We observed a significant protection after injection
of wild-type EV, compared to saline group17. Pre-treatment with miR-21-5p depleted EVs
produced a small but non-significant reduction of infarct size, suggesting other EV cargo
also contributed to the cardioprotection 17. The goals of Aim 2 were to investigate the effect
of miR-486-5p on in vitro and in vivo ischemia/reperfusion models and identify specific
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targets of miR-486-5p that are involved in the cell death/cell survival pathways.
Identification of specific function of miRNAs in EV cargo will facilitate the development of
novel EV RNA therapies against I/R injury 164.
MSC-EV miRNA Cargo and Their Predicted Targets and Function
Our small RNA deep sequencing data and other published profiling studies 167; 212; 213
show the EV miRNA expression levels are different from their producer cells. We detected
several miRNAs that have been implicated in I/R injury including miR-21-5p17; 214; 215; 216,
miR-22a-3p84, let-7b-5p217 (antiapoptotic), miR-126-3p218 (pro-angiogenic), but their levels
did not change in EVs compared to parent cells. We demonstrated that miR-486-5p is the
top upregulated miRNA in MSC-derived EVs, relative to producer cells. This result has
confirmed earlier findings showing miR-486-5p is the most abundant miRNA in human
bone marrow and adipose tissue MSC-derived EVs190.
Table 1. Top Candidate Cardioprotective EV-sorted miRNAs Identified by miRNASequencing
miRNA

Read per million
Cells
EVs

Targets

Mechanisms

Pten, Stau1, Dnajc21, Afl3,
Pdzm3, Cadm1, Mark1, Atg2b,
PDCD4
GATA4, ANKRD13C, APLNR,
TLR4, SIRT6, TGF CTGF
FOXO3, HNRPU

Cell death, Angiogenesis,
Adhesion, Autophagy, MAPK
regulation
Cell proliferation, Anti-fibrotic,
Collagen, RNA binding,
Transcription
Cell death, Mitosis, Metabolism,
Mitochondria oxidation, G-protein
signaling, GATA4 modulation
Inflammation, PKA signaling,
Cadherin regulation in apoptosis,
Myoblast fusion/development

miR-486-5p

6.35

10715.1
8

miR-122a-5p

1.85

5308.91

miR-451a

1.39

1355.29

CUGBP2, Zpf207, Ccr4, NEK2,
CISD1, Arr3, Zfpm2

miR-150-5p

0.31

1114.54

CXCR4, Zpf711, CRP, c-Myb,
Map3k3, Calcr, Eif5, Cbll1
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To select candidate miRNAs and their potential targets involved in cardioprotection,
we performed miRNA-Seq analysis of MSC-derived EVs (N=3). Sequencing data
demonstrated that many miRNAs are highly enriched in the EVs compared with their
parent cells. Some miRNAs were exclusively expressed in the EVs but not in the cells (Fig. 4
and Table 2). EV-enriched miRNAs that target genes predicted to be injurious in I/R injury
were revealed by two online algorithms MiRanda and Targetscan version 7.1 in silico
analyses. This narrowed the focus to four miRNAs of interest, of which miR-486-5p is the
most highly enriched followed by miR-122a-5p, miR-451a and miR-150a (Table 2). This
result provided preliminary data for selection candidate miRNAs and their protein targets
associated with cardioprotection.
Notably, miR-122a-5p has been shown to promote apoptosis, oxidative stress,
inflammation, collagen and extracellular matrix deposition in cardiovascular diseases. The
gene for miR-122a-5p was located within chromosome 18 in the mouse. In an
hypoxia/reoxygenation model employing rat cardiomyocytes, increased expression of miR122a-5p was associated with increased apoptosis and generation of ROS, whereas
inhibition of miR-122a-5p with antagomir was cardioprotective through modulating its
target GATA-4219. Inhibition of miR-122a-5p also alleviated lipid accumulation and reduced
secretion of inflammatory cytokines through the TLR4/MyD99/NF-kBp65 axis220. Further,
miR-122a-5p has been confirmed to target the important regulator of cardiac fibrosis and
remodeling Sirtuin 6 (SIRT6), promoting autophagy and apoptosis in rat aortic adventitial
fibroblasts221. The upregulation of miR-122a-5p was associated with the development of
cardiac hypertrophy with Angiotensin II stimulation through attenuation of FOXO3 and
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activation of calcineurin signaling

pathway222.

However, miR-122a-5p was reported to

inhibit ischemic neuronal cell death through HSP-70 mediated NF- B pathway by targeting

FOXO3223.

Previous studies have suggested the protective role of miR-451a in the heart. miR451a works in a synergistic manner with miR-144, to which it is linked in a miRNA cluster,
to confer protection against MI-induced cardiomyocyte death through targeting CUG triplet
repeat-binding protein 2 (CUGBP2)-COX2 pathway224. Genetic deletion of miR-144/451a
cluster impaired the efficacy of IPC-mediated cardioprotection on infarct size and
functional recovery after I/R225. Rac-1, a downstream effector of CUGBP2-COX2, was
targeted by miR-144/451a to contribute to IPC-elicited action225. In another study,
upregulation of miR-451a was demonstrated to be cardioprotective in reduction of infarct
size, release of creatine kinase, LDH and apoptotic index through inhibition of HMGB1, a
non-histone nucleoprotein that can promote autophagy and inflammation 226. Furthermore,
miR-451a was down-regulated in heart tissue of hypertrophic cardiomyopathy patients 227.
Knockdown miR-451a increased the cell size, whereas overexpression of miR-451a
reduced the cell surface area in neonatal rat cardiomyocytes via targeting tuberous
sclerosis complex 1 (TSC1)227.
Lastly, miR-150 is another miRNA that has been shown to underlie the progress of
cardiac disease. Circulating levels of miR-150 were reported to be down-regulated in
patients with LV-remodeling after first ST-segment-elevated acute MI event228. CRP and
ADRB1, two genes associated with LV remodeling, were confirmed to be regulated by miR150228. On the other hand, miR-150 deficient mice had impairment in cardiac function and

structure as well as increased in mortality after permanent ligation of

LAD229.
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This effect

appeared to be via direct suppression of egr2 and p2x7r, pro-apoptotic proteins229. In one
study, ectopic expression of miR-150 significantly reduced infarct size, inhibited apoptosis
and alleviated inflammation after acute MI 230. The author reported that mechanistically
miR-150 promoted monocyte migration by targeting chemokine receptor 4 (CXCR4)230.
However, there was a report about the up-regulation of miR-150 in cardiomyocytes after
H2O2 treatment and aggravated oxidative stress-induced injury by inhibiting c-Myb,
whereas opposite effects were observed when miR-150 was silenced231.
Overall, it seems the function of extracellular miRNAs is still a matter that requires
further research in different cell types. The functional studies described above suggested
that some EV derived-miRNAs such as miR-150a, miR-451a are protective and beneficial to
target cells, whereas other miRNAs such as miR-122a are ineffective or injurious. Thus, we
would hypothesize that modulation of EV-miRNA sorting will increase the loading into EVs
of beneficial miRNA and apply them to clinical settings as well as interest to decrease the
production and release of detrimental miRNAs in EVs.
Target Genes that Mediate miR-486-5p Function in Cardiomyocytes
The most highly enriched miRNA in MSC-EVs was miR-486-5p, 5853-fold higher in
EVs than in cells (Fig. 4). After miR-486-5p levels in EVs were validated by qRT-PCR (Fig.
19), we chose miR-486-5p to determine whether this miRNA contributes to the
cardioprotective effects of EVs. Recently, the link between miR-486-5p and MI has become
more apparent. It was reported that miR-486-5p is positively regulated by hypoxiainducible factor-1a (HIF-1a), a transcriptional regulator in cellular response to hypoxic
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conditions201.

Expression of miR-486-5p was reduced in H9c2 cells after hypoxia

treatment232; 233 or in H2O2-induced cardiomyocyte apoptosis234. Overexpression of miR486-5p with lentiviral vector increased cell viability and decreased cell apoptosis by
targeting Pten233, NDRG2232, or p53234. In the current study, we predicted PDCD4 and Pten
as the most likely potential target genes of miR-486a-5p using bioinformatic analysis (Fig.
20). Results if luciferase assay using the

-UTRs of PDCD4 and Pten showed a dose-

response relationship in reducing luciferase activities by miR-486-5p mimic (Fig. 22).

Transfection with miR-486-5p mimetic into H9c2 cells significantly reduced both mRNA
and protein level of PDCD4. Pten protein level did not change significantly after 48 hours
though there was a reduction in its mRNA levels after 24 hours post-transfection. These
results suggested PDCD4 is a definite target of miR-486-5p (Fig. 23). It is of note that our
result is in contrast with previous studies, in which miR-486-5p was reported to suppress
protein expression of Pten, and its downstream target, pAkt 194; 195; 233. We did investigate
PTEN, since it was the second most likely miR-486-5p target, and in fact found an effect
upon PTEN mRNA levels of miR-486-5p treatment. However, we did not find effects upon
protein levels of PTEN, or its target Akt, at least in the time frame we chose, which is
relevant to cell death and survival in our models (Fig. 23). We observed a trend toward
reduction of Pten in the group treated with miR-486-5p mimic after simulated I/R injury
(Fig. 27). A post-hoc power analysis indicated that this decrease was significant if we had
increased the sample size to approximately 8 per group. So it may be that the lack of
significance in our study was due to sampling error. Another possible explanation for the
difference between the studies is the longer half-lives for Pten (10 hours)235 than PDCD4

(4

hours)236
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or the difference in method of overexpressing miR-486-5p. It may be that the

link between miR-486-5p and protein expression of Pten is cell type-specific, or that we
simply did not detect an effect that occurred at a slightly later time point. However, if the
latter is true, we would question the relevance of this effect to cardioprotection in our
model and our results support that PDCD4 is the more relevant target.
Some studies have suggested a regulatory loop between Pten, PDCD4, miR-215p/miR-486-5p. Downregulation of Pten by miR-21-5p and miR-486-5p enhance Akt
activity17; 195. Akt can directly phosphorylate PDCD4, causing its inactivation and nuclear
localization. The phosphorylation of PDCD4 by Akt reduces the ability of PDCD4 to
suppress the activation of activator protein 1 (AP-1) in initiating protein synthesis 237 and
to induce cyclin-dependent kinase inhibitor p21 in reducing cell proliferation 238. Additional
studies are needed to dissect the coordinated suppression of Pten and PDCD4 in the
context of cardiomyocytes.
Because a single miRNA can target more than 1,000 target mRNAs, and each gene in
turn can be regulated by many different miRNAs239, the relationship between miR-486-5p
and PDCD4 has not been investigated before. In this study, we aimed to explore whether
miR-486-5p can induce cardioprotection against cell death-mediated by I/R injury by
attenuating PDCD4. This is the first study demonstrating miR-486-5p negatively regulates
the tumor suppressor PDCD4 at the post-transcriptional level via binding in the

-UTR of

the mRNA. PDCD4 is a known tumor suppressor, regulating apoptosis via interaction with
initiation factor eIF4A and eIF4G to suppress their translation240. Besides that, PDCD4 was
reported to be upregulated in cellular senescence and apoptosis 241. PDCD4 deregulation
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has been found to be associated with several types of CVD. Myocardial expression of PDCD4
increases up to 24 hours after coronary microembolization induction in pig 242. In coronary
arteries of atherosclerotic rats, PDCD4 is up-regulated and contributes to the formation of
coronary plaques and promotes inflammation243. Genetic knockdown of PDCD4 improves
left ventricular function and reduces myocardial apoptosis in a type 2 diabetic rat 244. Also
atorvastatin therapy has been shown to reduce myocardial inflammation by inhibiting
PDCD4 expression in CD4+ T lymphocytes of patients with unstable angina who received
percutaneous coronary intervention245. Data from several studies suggest the protective
effect of miRNAs in MI is through targeting PDCD4. For example, PDCD4 is a direct target of
several miRNA including miR-21-5p17; 215, and miR-499246; 247 in cardiomyocytes resulting
in inhibition of apoptosis-induced cardiomyocytes death in response to H2O2 stimulation or
simulated I/R in cell culture. In this study, we also found miR-486-5p protected
cardiomyocytes from ischemia reperfusion-induced apoptosis via targeting PDCD4.
Myocardial apoptosis is associated with cardiac dysfunction after MI248. The
apoptotic process is mediated by the regulation of many genes, including Caspase-3 and
members of the Bcl-2 family. Our in vitro data showed that pretreatment with miR-486-5p
reduces cleaved caspase-3 and Bax expression after simulated I/R. This finding is
consistent with previous studies which demonstrated PDCD4 signals through the caspase3, Bax pathway198; 199. Furthermore, in vivo administration of miR-486-5p mimic via
pericardial sac injection was protective against I/R injury in vivo (Fig. 28). These results
suggest that miR-486-5p has cardioprotective effect and may act as anti-apoptotic miRNA
via its functional target PDCD4. Given previous roles of miR-21-5p in other studies17; 215
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and miR-486-5p in this study in alleviating cardiomyocyte cell death via suppressing
PDCD4, we would propose that the common action at this target by MSC-EV associated
miRNAs is a key part of the powerful cardioprotective effect of MSC-derived EVs.
Limitations and Future Directions
Recently, the interaction of RBPs and miRNA has been shown as an important
sorting mechanism for vesicular miRNAs 77; 78; 79; 94; 95. In this study we identified
hnRNPA2B1 binds to miR-486-5p and facilitates the sorting of miR-486-5p in EVs.
However, we may not have a clear picture on how many RBPs may form complexes with
miR-486-5p and other EV-enriched miRNAs to shuttle them into EVs. For example,
caveolin-1 was found to form a complex with hnRNPA2B1 to bind with miR17/93 208, while
microtubule-associated protein 1A/1B-light chain 3 (LC3) was reported as a interactor of
hnRNPK to control the loading of EV cargo249. This could be due to their slight expression in
EVs or their decent affinity to specific small non-coding RNA molecules. As a result, we may
miss identifying all RBPs that are essential for the sorting of miRNAs into EVs. Future
studies on the relationship of RBPs and mechanism of trafficking of miRNAs to secreted
vesicles will involve quantitative measurement of protein localization, efficiency of RNAprotein interaction at intracellular and vesicular level. In addition, the role of secondary
RNA structures in binding of miRNAs and RBPs is another important future direction. For
instance, YBX1 was suggested to recognize miR-233 for sorting into HEK293T-derived EVs
via recognition motif on secondary structure rather than primary RNA sequence. Taken
together, these approaches will elucidate how the loading of miRNAs into EVs is
modulated.
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One of the limitations in our study is the physiologically relevant amount of miR486-5p mimic used in experiments. To study the function of miR-486-5p in recipient cells,
we transfected H9c2 cells with 50-100 nM of miRNA mimetics or scramble non-targeting
miRNA, corresponding to 50-100 pmol or 3x1013- 6x1014 copies of miRNA in the medium.
Transient transfection miR-486-5p mimics led to 400 fold increase in mature miR-486-5p
levels (Fig. 23A) and 50% inhibition in protein level of PDCD4 (Fig. 23D). In a previous
study, we observed a protective effect when cells were pre-treated with 300 µg proteins of
WT-MSC-derived EVs17. The number of particles that corresponds to 1 µg EVs protein has
been estimated at 2x109- 2x1010 particles250; 251 in the conditioned medium. If there was an
average of 0.01 copy of miRNA of interest per particle based on previous stoichiometric
studies252; 253, a maximum of 6x109 to 6x1010 copies of specific miRNA were present in the
medium. Comparison of the miRNA mimics used for transfection and the miRNA content in
the EVs showed a large difference in miRNA copy number in the order of 10 4- 105,
indicating the superior transfer efficiency of EVs over conventional transfection reagents.
Another limitation is that no single RNA species can account for all the benefits of
EVs. Administration of miR-486-5p alone might mask the protective effect of other miRNAs,
as well as other RNA species and proteins found in EVs. This has been seen in the case of
miR-146a, the most highly enriched miRNA in CDC-derived EVs relative to producer cells 19.
CDC-EVs containing miR-146a reduced apoptosis and enhanced angiogenesis in vitro, as
well as improved cardiac functions and increased viable mass after MI in vivo. Level of miR146a elevated in infarcted animals treated with CDC-derived EVs, suggesting the critical
role of miR-146a in CDC-EVs protective properties However administration of miR-146a
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mimic alone did not reproduce all therapeutic effects of CDC and CDC-EVs. While miR-146a
mimetic protected neonatal cardiomyocytes against oxidant stress, EVs deficient in miR146a are still suppressed apoptosis, much as our miR-21-5p deficient EVs17. In a chronic
model of MI, miR-146a mimic failed to decrease scar mass and improve global function,
while increasing viable mass. From these studies and from our own, it seems that multiple
miRNAs may be needed to confer comprehensive cardioprotective benefits of CDC-EVs. The
author of the abovementioned work suggested that detailed analysis of active components
within EVs is worthwhile, but intact particles may be required for therapeutic application 19.
Our small RNA sequencing data demonstrated the presence of other miRNAs that may
work synergically with miR-21-5p and miR-486-5p. For example, miR-22 modulates the
adaptive responses to cardiac stress via cardiac expression of SERCA and myofibrillar
genes254. Likewise, miR-24 has been shown to be critical for cardiac fibrosis after MI by
targeting furin, a protease which participates in the activation of TGF-

Overexpression of

miR-24 reduced formation of fibrosis in the infarct border zone in a model of MI 255.
On the other hand, we also detected the presence in EVs of miR-122a whose
deleterious role in cardiomyocyte apoptosis has been reported in several studies. This
observation suggests that EVs can serve as a carrier for unnecessary or even injurious
cargo as well as beneficial cargo. This raises the question whether EV selectively sorted
miRNAs work together or not. There could, if course, be other functions of miR-122a that
outweigh the injurious aspects. It also could be that different EV subpopulations contain
somewhat different populations of miRNAs; to date there are not good procedures for
isolating homogenous EVs in the numbers needed for these types of experiments. New and
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standardized methods for EV isolation and purification are needed. Perhaps affinity
purification based on antibodies against EV surface markers such as CD9, CD81, TSG101, or
Alix may reveal EV subpopulations carrying unique miRNA cargo and allow us to further
refine our work.
In addition to identifying potential miRNA candidates controlling the
cardioprotection, future studies of other non-coding RNA subtypes will be needed. In fact,
miRNAs are a minority of exosomal RNA. For example, less than 7% of RNA in CDC-derived
EV is miRNAs, but 18% were Y-RNA256. In one study, EV-derived Y-RNA fragment 1 (EVYF1) was found to be anti-hypertrophic, and anti-fibrotic and to improve renal function in a
model of cardiac hypertrophy and renal damage induced by Angiotensin II infusion 257. The
hypertrophy associated with Ang.II infusion was antagonized by EV-YF1 to the same extent
that it was antagonized by EVs. The anti-fibrotic effect was also reproduced by YF1, and the
renal function was improved by a reduction in proteinuria into similar degrees by YF1 as
compared to the parent EVs. Additionally, long non-coding RNAs are another EVs cargo
that needs to be studied further. Recently a study has demonstrated that EVs isolated from
human MSC pretreated with macrophage migration inhibitory factor can horizontally
transfer lncRNA nuclear assembly transcript 1 (NEAT1) to cardiomyocytes142. LncRNANEAT1 exerted cellular protection against H2O2-induced oxidative stress through
suppression miR-142-3p, leading to activation of this miRNA downstream target, FOXO1
transcription factor, an important factor in cardiac metabolism and cell survival. Silencing
lncRNA-NEAT1 or FOXO1, or over-expressing miR-142-3p blocked these antioxidant effects
of EVs. In another study, EVs isolated from atorvastatin-pretreated MSC protected
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cardiomyocytes from apoptosis induced by hypoxia and serum deprivation condition in
vitro, and reduced infarct size and improved cardiac function in a rat acute MI model. In
addition inflammation and expression of fibrosis genes were down-regulated while the
angiogenesis was promoted in MI hearts. MSC-EVs derived lncRNA H19 was thought to
functionally act through the activation of miR-675, VEGF and ICAM-1258.
In this project, we focused on the sorting mechanism and function of miRNA in
recipient cells. Ongoing projects in our laboratory are studying whether the internalization
of EVs occurs through direct membrane fusion/receptor-mediated endocytosis and how
EVs can be used in drug delivery. With the explosion of RNA-based therapeutics that we are
seeing, including mRNA vaccines against Covid-19, this is one of the most exciting
opportunities that biotechnology has seen in a long time.
Clinical Significance
Coronary heart diseases, including myocardial infarction, are the leading cause of all
cardiovascular diseases in both industrialized and developing countries. As a result, novel
cardioprotective therapies are desperately needed to prevent the detrimental adverse
effects of ischemia/reperfusion injury, thus attenuating adverse left-ventricle remodeling,
reducing heart failure and mortality in patients after acute MI. However, many
cardioprotective interventions for reducing infarct size in the laboratory settings failed or
yielded neutral results in the clinical settings. Stem cell transplantation has been an
attractive promising therapy for CVD. Several types of adult stem cells, including
mesenchymal stem cells, have been studied both pre-clinically and clinically for their
potential to repair injured myocardium, and improve cardiac function as well as patient
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outcome in MI. However, poor cell engraftment and the lack of transdifferentiation
potential of stem cells to cardiomyocytes have inspired the paracrine hypothesis that stem
cells have beneficial effects on the infarcted heart through secreted factors including
extracellular vesicles (exosomes and microvesicles). EVs are potential players in
interaction between different cell types and in inter-organ communication. Accordingly,
stem cell-free therapies offer an alternative to such cardioprotective strategies. There are
several advantages of using EVs instead of stem cells in MI. First, EVs can recapitulate
beneficial properties of their source cells while being more physiologically stable than cells
in terms of viability. Second, EVs are associated with low immunogenicity, therefore they
are not cleared from the blood by the immune system. Third, EVs can deliver bioactive
molecules including mRNA, non-coding RNAs, and proteins to recipient cells, and this cargo
can be modified by manipulating parent cells or by external means such as electroporation
or transfection. All of these features show promise for their application of EVs over
conventional cell-based approaches for myocardial salvage and repair.
We believe EVs hold great potential as the next generation of therapeutic candidates
and could have a large impact in clinical settings. The toxicity, biodistribution, half-life, and
dose estimation should be assessed in EV-mediated cardioprotection experiments to
determine the safety and procedures for EV delivery, dosing, and elimination. Future
studies should also investigate how long the beneficial effects of EVs might last for and
what factors are required to maintain these effects in the long term as well as multiple
dosing study. Furthermore, EVs could be used in combination with other cardioprotective
agents directed to different unrelated targets for complementary effects. This multi-
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targeted approach directed to different signaling pathways can be more effective in
cardioprotection.
Conclusions
In summary, the results represented here demonstrate that a selective group of
miRNAs are actively loaded into MSC-EVs and are cardioprotective. We found MSC-derived
EVs exhibit a distinctive miRNA profile, relative to parental cells, which might implicate
their biological function and therapeutic applications. We were able to identify miR-486-5p
as the most highly enriched in MSC-derived EVs and its sorting mechanism can be
explained by the interaction with RNA binding protein, hnRNPA2B1. The protective
features of miR-486-5p are mediated, at least in part through modulation of cardiomyocyte
apoptosis via PDCD4, in ischemia/reperfusion injury.
We provided evidence that EV enrichment of miR-486-5p and other miRNAs that
share a common sequence motif ugAGuu required hnRNPA2B1. The role of hnRNPA2B1 for
miRNA loading into EVs was confirmed by loss-of-function experiments. In the group of
MSC-EV-enriched miRNAs, miR-486-5p was the miRNA whose sorting was most
significantly modulated by hnRNPA2B1. We demonstrated interaction between miR-4865p and hnRNPA2B1 through several different in vitro binding assays, including
electrophoretic mobility shift assay, RNA immunoprecipitation and reciprocal biotinylated
RNA pull-down. The data demonstrate an important role of hnRNPA2B1 in the secretion of
miRNA in EVs derived from MSC cells. Understanding the machinery involved in EV loading
of miRNAs will provide targets for manipulating miRNA cargo of MSC-EVs.

113
On the functional role of secreted miRNA in the MSC-EV cargo, several of the
miRNAs loaded into EVs share potential targets that may play roles in cell survival, antiapoptosis, and angiogenesis. We focused upon miR-486-5p and were able to predict the
biological targets using bioinformatic analysis. Luciferase assay showed that miR-486-5p
targets

-UTR of PDCD4 and represses mRNA and protein expression in vitro. We did not

find evidence of cell toxicity of miR-486-5p in normoxic conditions. Pretreatment of miR486-5p mimetics increased H9c2 viability, and reduced the release of LDH as well as the
number of apoptotic cells after sim I/R. Meanwhile, the cardioprotective effects of miR486-5p were further confirmed in vivo by demonstrating infarct size reduction in an animal
model of MI after I/R injury. We validated the role of signaling pathway PDCD4/caspase3/Bax in the cytoprotective properties of miR-486-5p action. Collectively, the data
indicated that miR-486-5p regulates cell survival after I/R injury through suppressing
tumor suppressor PDCD4. Our laboratory previously demonstrated that miR-21-5p also
reduced apoptosis primarily through PDCD4 repression. Thus, the miR-486-5p:PDCD4 axis

may be a critical regulatory axis for apoptosis that is additively repressed by cooperative
action of several miRNAs from MSC-EVs, producing strong protection against cardiac I/R
injury.
Future studies in our laboratory will continue to identify and validate other factors
including RNA-binding proteins, specific sequence motifs or post-transcriptional
modifications that mediate the loading of miRNAs into MSC-EVs as well as investigate
functions of other EVs-enriched miRNAs whose expression levels were significant reduced
in hnRNPA2B1 knock-out experiment including miR-150 and miR-369. In humans, more
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than 1500 proteins have been predicted and experimentally determined to modulate RNA
metabolism through binding and processing RNA or being essential part of the
ribonucleoprotein complex259. Thus we speculate that the binding preference of RNA
binding proteins to miRNAs is cell type specific, depending upon which miRNAs and
proteins are present in a specific cellular compartment. In addition, some cell types may
use multiple RNA-binding proteins to load RNAs into EVs. Furthermore, we will continue
mining of EV contents beyond miRNAs to identify defined factors that mediate beneficial
and injurious effects of MSC-derived EVs. Finally, we can combine understanding of sorting
mechanisms, function of RNA species with uptake mechanisms for potential recipient cells
from other ongoing projects in our laboratory to create a comprehensive profile of MSCderived EV cargos by function. We predict that new insight into small vesicles released
from MSC and their cargoes may regulate protection of the heart following myocardial
infarction will lead to new cell-free therapies that can improve long-term patient
outcomes.
MSC-EVs mediated cardioprotection is highly translational as MSC-EVs can
recapitulate the benefits of MSC therapies while possessing emergent properties such as
extended shelf-life, less immunogenicity, and readily manipulable post-production. Initially
regarded as means to dispose of cellular waste, EVs are now considered as potential
therapeutic and diagnostic markers. It is my hope that data from this dissertation will help
establish a rationale and new targets for the development of EV therapies engineered to
maximize therapeutic effects, minimize adverse effects and improve patient outcome in the
cardiovascular diseases area and beyond.
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